


SCIENCE · INNOVATION · POLICIES

WORLD HEALTH SUMMIT BERLIN, GERMANY OCTOBER 14-16, 2018 www.facebook.com/worldhealthsummit www.linkedin.com/company/worldhealthsummit/ www.twitter.com/WorldHealthSmt Hashtag: #WHS2018



WORLD HEALTH SUMMIT BERLIN, GERMANY OCTOBER 14-16, 2018

SUNDAY | OCTOBER 14, 2018

	SAAL 1 RUDOLF VIRCHOW	SAAL 6 EUROPE	SAAL 10 ASIA	SAAL 2 AMERICA	SAAL 4 AFRICA	SAAL 5 OCEANIA
		PD 01 Page 40	WS 01 Page 42	WS 02 Page 44	WS 03 Page 46	WS 04 Page 48
11:00- 12:30		Migration and Refugee Health M8 Alliance University of Montreal	Food Systems, Nutrition and Health InterAcademy Partnership (IAP) German National Academy of Sciences Leopoldina e.V.	Optimizing Health in Aging Societies Kyoto University M8 Alliance Max Planck Society National Taiwan University (NTU) University of Rostock	Bridging the Valley of Death European and Develop- ing Countries Clinical Trials Partnership (EDCTP) Foundation for Innova- tive New Diagnostics (FIND) Max Planck Society	Building the Future of European Health Research European Commission
Lunch Br	reak (90 min)					
		PD 02 Page 50	WS 05 Page 52	WS 06 Page 54	WS 07 Page 56	WS 08 Page 58
14:00 - 15:30		Managing the Next Decade in Cancer International Prevention Research Institute (iPRI) Pfizer	Addressing the Gender Dimensions for Health Systems Strengthening Research in Gender Ethics (RinGs) Women in Global Health	Inequality and Mental	International Life Sciences Location and Infrastructure Management Ministry of Economic Affairs Canton of Bern M8 Alliance	Digital Medicine in Real Life Charité - Universitäts- medizin Berlin M8 Alliance Sanofi
Coffee B	reak (30 min)					
		PD 03 Page 60	WS 09 Page 62	WS 10 Page 64	WS 11 Page 66	WS 12 Page 68
16:00 - 17:30		An Integrated Response to Obesity, Diabetes, and NCDs Sanofi The NCD Alliance World Health Organization (WHO)	Respect and Dialogue InterAcademy Partnership (IAP) International Partnership on Religion and Sustain- able Development (PaRD)	Ensuring Patient Safety in Hospital Management Charité - Universitäts- medizin Berlin Imperial College London MB Alliance National University of Singapore (NUS)	Falsified and Sub- Standard Medicine Association of Research- based Pharmaceutical Companies (vfa)	Preventing Dementia by Preventing Stroke Charité - Universitäts- medizin Berlin M8 Alliance World Dementia Council (WDC) World Stroke Organization (WSO)
	KEY 01 Page 70					
18:00 - 19:30	Opening Ceremony M8 Alliance					
19:30 - 22:30	Welcome Reception					

MONDAY | OCTOBER 15, 2018

	SAAL 1 RUDOLF VIRCHOW	SAAL 6 EUROPE	SAAL 10 ASIA	SAAL 2 AMERICA	SAAL 4 AFRICA	SAAL 5 OCEANIA
		PD 04 Page 74	WS 13 Page 76	WS 14 Page 78	WS 15 Page 80	WS 16 Page 82
9:00 - 10:30		Global Health Security Munich Security Conference (MSC)	Growth & Resilience Bill & Melinda Gates Foundation Grand Challenges	One Health Leibniz Association German Federal Ministry of Education and Research (BMBF)	Neglected Tropical Diseases and their Co-Morbidities Association of Research- based Pharmaceutical Companies (vfa) Eberhard-Karls- University Tübingen German Network against Neglected Tropical Diseases (DNTDs) German Society for Tropical Medicine and International Health (DTG) Universitätsklinikum Tübingen	Better Leadership: Improved Health ESMT European School of Management and Technology GmbH InterAcademy Partnership (IAP)
Coffee E	Rreak (30 min) KEY 02 Page 84	PD 05 Page 86			WS 15a Page 88	WS 16a Page 90
11:00 - 12:30	Vaccine Production and Delivery Systems Bill & Melinda Gates Foundation	Value Based Health Care National University of Singapore (NUS)			Digital Integration of Surveillance and Outbreak Response Management	Disease X German Institute for Defence and Strategic Studies (GIDS)
	Heidelberg Institute of Global Health PATH	M8 Alliance			Helmholtz Centre for Infection Research (HZI)	Global Health Security Alliance
Lunch B	of Global Health PATH reak (90 min) World H	Health Summit Startup Tra	ack Pitch Competition		Infection Research (HZI)	Alliance
Lunch B 14:00 - 16:00	of Global Health PATH		ack Pitch Competition			
14:00 - 16:00	of Global Health PATH reak (90 min) World H KEY 03 Page 92 Antimicrobial Resistance German Federal Ministry of Education and Research (BMBF) German Center for Infection Research e.V. (DZIF)	PD 06 Page 94 Big Data Analytics in Biomedical Research and Healthcare Berlin Institute of Health (BIH) Charité - Universitäts-medizin Berlin	ack Pitch Competition		WS 15b Page 96 The Beauty of Impact: Disruptive Innovations for Food-Related Health Challenges	WS 16b Page 98 Healthcare Systems in Latin America Cluster Médico Jalisco Ad German Healthcare Partnership (GHP) Joint United Nations Programme on HIV/AID
14:00 - 16:00	of Global Health PATH reak (90 min) World H KEY 03 Page 92 Antimicrobial Resistance German Federal Ministry of Education and Research (BMBF) German Center for Infection Research e.V. (DZIF) Robert Koch Institute	PD 06 Page 94 Big Data Analytics in Biomedical Research and Healthcare Berlin Institute of Health (BIH) Charité - Universitäts-medizin Berlin	ack Pitch Competition	WS 18 Page 104	WS 15b Page 96 The Beauty of Impact: Disruptive Innovations for Food-Related Health Challenges	WS 16b Page 98 Healthcare Systems in Latin America Cluster Médico Jalisco Ar German Healthcare Partnership (GHP) Joint United Nations Programme on HIV/AID

TUESDAY | OCTOBER 16, 2018

	SAAL 1 RUDOLF VIRCHOW	SAAL 6 EUROPE	SAAL 10 ASIA	SAAL 2 AMERICA	SAAL 4 AFRICA	SAAL 5 OCEANIA		
		PD 08 Page 112	WS 21 Page 114	WS 22 Page 116	WS 23 Page 118	WS 24 Page 120		
9:00- 10:30		Health Systems Strengthening Johns Hopkins Bloomberg School of Public Health M8 Alliance	Digital Health in Developing Countries Federal Ministry for Economic Cooperation and Development (BMZ) German Society for International Coopera- tion (GIZ)	Cities as Drivers of Global Health InterAcademy Partnership (IAP) International Society for Urban Health (ISUH) World Federation of Academic Institutions for Global Health (WFAIGH)	Population based Cohort Studies and Health Prediction Charité - Universitäts- medizin Berlin MB Alliance Max-Delbrück-Centrum für Molekulare Medizin (MDC)	Developing Global Health in Academic Institutions and Medical Centers Charité - Universitäts- medizin Berlin M8 Alliance Makerere University Tehran University of Medical Sciences (TUMS)		
Coffee B	Coffee Break (30 min)							
		PD 09 Page 122	WS 25 Page 124	WS 26 Page 126	WS 27 Page 128	WS 28 Page 130		
11:00 - 12:30		Innovation for Impact Bill & Melinda Gates Foundation Grand Challenges	Access to Essential Medicines International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)	Challenges and Breakthroughs on the Road to Universal Health Coverage Federal Ministry for Economic Cooperation and Development (BMZ)	Protecting Public Health following Environmental Disasters London School of Hygiene & Tropical Medicine (LSHTM) MB Alliance Monash University	Medical Research in Outer Space German Aerospace Center (DLR)		
Lunch B	unch Break (60 min)							
	KEY 04 Page 132	PD 10 Page 134						
13:30- 15:00	Healthy Lives and Well-being for All World Health Organization (WHO) World Health Summit	The Digital Healthcare Revolution Commonwealth Centre for Digital Health Global Digital Health 2030 Innovation Task Force						
Coffee B	Break (30 min)							
	KEY 05 Page 136							
15:30 - 17:00	The SDG3 Global Action Plan for Health and Well-Being World Health Organization (WHO) World Health Summit							
Break /	Break / Transfer							
	JKEY Page 138							
18:00 - 20:00	Joint Keynote Grand Challenges/World Health Summit @ Estrel Hotel Berlin							

Welcome Messages 8

- High Patrons 8
- World Health Summit Presidents 12
- Charité 15

Key Facts 16

Mission 17

Topics 2018 18

World Health Summit 20

- Presidents 20
- Scientific Committee 21
- Ambassadors and Council 22

M8 Alliance 24

- Mission 24
- Member Institutions 25
- Goals 26
- Leadership 27

World Health Summit 32

- Startup Track 32
- Summit Night 34
- New Voices in Global Health 36

Program 39

- Sunday, October 14, 2018 39
- Monday, October 15, 2018 73
- Tuesday, October 16, 2018 111

General Information 141

- Directions 142
- A-Z 144
- City of Berlin 148
- Speaker Index 150
- Supporting Institutions 152
- Partners 154
- Media Information 159
- Contacts 160
- Imprint 162

ANGELA MERKEL



Angela Merkel

Health is our most precious asset. Health is a human right. Health is not only the responsibility of the individual. The international community has set itself the goal of ensuring that every woman, man and child in the world has the chance of a healthy life. The World Health Summit shows that this goal does not have to remain

a mere wish. This extraordinary dialogue forum is a particularly rich source of new solutions and ideas of benefit to humankind, so I was happy to take on the patronage of the event once again, along with President Emmanuel Macron and the President of the European Commission, Jean-Claude Juncker.

No matter where people live, health risks and the medical care available determine whether they can live in dignity. In turn, health risks and medical care are influenced by a large number of different factors. Growth and prosperity, crises and conflicts, education and information, the climate and environment, and demographic and social developments all have an impact on the health of the individual. The catalogue of goals in the 2030 Agenda for Sustainable Development highlights correlations and links – and thus also reveals the need for health to play a role in numerous policy fields and shows why we need a global health policy.

It cannot be underlined often enough that in a world of increasing interdependence among the

ways globalization determines the fate of individual countries, joint efforts by the international community and collaboration between the political sphere, academia, the business sector and society are also needed as regards health and quality of life.

Naturally, the priority is that each country ensures it has a functioning and efficient healthcare system. But like other industrialised nations with a strong research sector, Germany has a particular responsibility. Whether we are talking about preventing pandemics, counteracting antimicrobial resistance or tackling neglected diseases, our future global well-being will largely depend on scientific findings. That is why we want to enhance our global health policy endeavours in the field of research and development in particular.

Giving every woman, man and child in the world the chance of a healthy life deserves our full attention, the best ideas and active cooperation. The World Health Summit has proved to be extremely important and helpful in this regard. I am delighted that so many experts will meet here to share their knowledge and experiences and draw up recommendations. All of you are helping to make the world more humane. Thank you for that and welcome to the World Health Summit 2018!

Cupe Whil

Angela Merkel

Chancellor of the Federal Republic of Germany

EMMANUEL MACRON

Health is a common good, which has particular value, for each of us, and for the global community. As such, it can bring double returns: investing in health carries benefits both for economic development, and for the progress of humanity. Health is precious and valuable for each individual, and can only be guaranteed through action and commitment on a global scale: that is what we, the international community, set ourselves to achieve through the sustainable development goals.

There have already been great collective successes, which we can build upon. Almost twenty years ago, the international community committed to fighting the three most devastating infectious diseases by launching the Global Fund against AIDS, Tuberculosis and Malaria. France has played a pioneering role in this fight through scientific research, and by promoting the rights of people affected by AIDS, TB and malaria. France is the historical second-largest donor to the Global Fund, contributing €4.2 billion since 2002. On October 10th, 2019, France will host the next Global Fund replenishment conference. in order to leverage funds for the 2020-2022 period. This commitment is grounded in our belief in the efficiency of a multilateral and sustainable response to global health issues. I know we share this vision with Germany, host of the World Health Summit, and with many of our partners.

To effectively "Ensure healthy lives and promote well-being for all at all ages" by 2030, we must keep addressing several global health challenges

in an increasingly coordinated and integrated way: health systems strengthening to achieve universal health coverage with access to essential quality medicines and vaccines, response to health emergencies, antimicrobial resistance (AMR), digital health-care revolution, etc.



Emmanuel Macron

The "Health in all policies" approach is key to achieve this. In our interconnected world and societies, we will not sustainably improve health without fighting climate change, nor without guarantying access to education and empowering women and girls. This is why protecting our planet and reducing inequalities will be at the heart of France's G7 presidency.

We will build upon our active involvement through the implementation of health projects in developing countries through the Agence Française de Développement and long-term support to support other key multilateral partnerships – GAVI and UNITAID – as well as the World Health Organization, the lead international organization for global health.

We will keep promoting innovation, critical to achieving our ambitious sustainable development goal for health. We need to move at a quicker pace, we need to achieve more, to be more efficient. We must develop new methods of diagnosis, new drugs and alternative treatments, new approaches in prevention approaches. Innovation

is also key for ensuring sustainable access to existing therapies for all those in need. This is particularly crucial to improve the response to health emergencies. France is joining the World Health Organisation's efforts by hosting this year's WHO high-level conference on crosssectoral coordination in response to public health emergencies in Lyon on 3-4 December. It is also crucial to tackle AMR, the global phenomenon currently compromising our collective ability to treat infectious diseases - we believe the integrated One Health approach can be particularly effective in this respect. Collective action is necessary, and France supports the creation by Germany as well as other partners of the "Global AMR R&D HUB".

Over the years, the World Health Summit has become a major forum for addressing global health issues in a cross-cutting manner by bringing together all relevant stakeholders on an international level, especially this year for its tenth anniversary and thanks to the partnership with the Grand Challenge Annual Meeting.

I am proud to give my patronage to this Summit, and would like to join the Chancellor of the Federal Republic of Germany and the President of the European Commission in wishing you all an excellent and productive meeting.

Emmanuel Macron

President of the Republic of France

It is my great pleasure to offer my patronage once more to the World Health Summit, and to congratulate you on reaching the important milestone of your ten year anniversary. The World Health Summit is in good health!

The European Union is also in better health this year, with economic growth in every Member State, almost 12 million jobs created since this European Commission's mandate began in 2014, and public deficits down from an average of 6.6% in 2009 to 0.8% in 2018. This healthy economic picture matters for our citizens' health, because it allows us to plan for the investments we need to make in our healthcare and social systems, and in research and innovation.

This year the Commission presented its long-term budget proposals for the years 2021-2027. Health will be a strong focus. We have proposed a spending increase of 50% for research and innovation, reflecting the strong added value of European cooperation in this field. For example, major advances have been made on cancer treatment thanks to EU research, and 1.6 million Ebola vaccine doses have already been produced and stockpiled for emergency use thanks to EU funding.

Health is also a dedicated focus of the renewed European Social Fund, which will be worth €101.2 billion over seven years, with the health strand receiving €413 million. We will focus on the priority areas where EU cooperation has a proven benefit: strengthening cross-border

crisis-preparedness, assisting Member States' health authorities, digitising health and care, supporting EU health legislation and enhancing cross-border cooperation, for instance on rare and complex diseases.

In recent months, we have seen a renewed debate and increasing

disinformation spread about vaccination. It can be no coincidence that we also see diseases such as measles on the rise in Europe. It is unacceptable that there are still children dying of diseases that should have been eradicated long ago. This is why we are working with all Member States to support national vaccination efforts, and it is why I asked my Health Commissioner Vytenis Andriukaitis to propose a new set of recommendations in April 2018 to strengthen our efforts to fight diseases which can be prevented by vaccination.

I hope the World Health Summit will stimulate an interesting discussion on these topics, and more, and I wish you all the best for another inspiring gathering and another successful year ahead.



Jean-Claude JunckerPresident of the European Commission



Jean-Claude Juncker

WORLD HEALTH SUMMIT PRESIDENTS







Fernando Regateiro



Detley Ganten

WELCOME TO THE WORLD HEALTH SUMMIT 2018

Science has to take responsibility! Our common future is already determined by research and by new technologies emerging from new knowledge, and this process continues to gain speed. We have to make sure that today's amazing developments are used to benefit all of humankind. This is what people expect from the progress. Health and wellbeing is what people are most concerned about. Health may be a human right but when it comes to health, the world is in a worrisome state. The chief causes of death are shifting from infectious to non-communicable diseases, while climate change, political instability in many regions, economic crisis, migration and flight are all contributing factors in major health issues.

Meanwhile, the world's population continues to grow and to age. The global burden of disease remains, and is even on the rise in some areas. We are not living up to expectations.

Ever since the first World Health Summit on the occasion of the 300th anniversary of the Charité – Universitätsmedizin Berlin, we have been working towards one goal: improving health for everyone on the planet. We have to respond to the most important global health challenges, and must find fast and efficient ways to bring medical advances to the places where people are in need. But each of us can do very little alone. That's why from the beginning, the World Health Summit has brought

together stakeholders and decision-makers from every sector, from all over the world. By combining forces from academia, the private sector. industry, civil society and politics, we have been able to achieve change and improve health worldwide. And there are now some very promising leads on how we can do even more. Around the globe, the M8 Alliance of Academic Health Centers. Universities and Academies of Medicine and Sciences provide a unique think tank for the World Health Summit program in academic freedom. A milestone - and an encouraging sign is the prominent position that health topics have assumed on the agendas of the G7 and G20 meetings. From the very beginning, the World Health Summit has enjoyed support from the highest level of politics, with ongoing high patronage from the Chancellor of Germany, the President of the French Republic and the President of the European Commission.

The Sustainable Development Goals (SDGs) and Agenda 2030 provide the framework for a holistic health approach in every area of policymaking. We are glad to see the WHO and other key organizations playing an increasingly supportive and coordinated role in achieving these goals in tandem with the United Nations and the World Health Organization. We need efforts that are transdisciplinary, science-based, cross-sectoral and concerted. They are vital to set the global health agenda for global health for the years to come. Participants from all over the world bring different views, experiences and priorities. They aren't only welcome - they're the very essence of the World Health Summit vision, mission and philosophy. We hope you'll be able to join us on October 14th to 16th at the World Health Summit in Berlin, as we lay the cornerstones for global health in the coming era!

João Gabriel Silva

Acting International President Rector, University of Coimbra, Portugal Fernando Regateiro

Acting International President Chairman of the Board of Directors, Coimbra University Hospitals, Portugal **Detley Ganten**

World Health Summit Founding President Charité - Universitätsmedizin Berlin Germany











Axel Radlach Pries

DEAR WORLD HEALTH SUMMIT PARTICIPANTS,

As one of the largest and most influential university hospitals in Europe, the Charité – Universitäts-medizin Berlin must strive to secure the very best healthcare for its patients and all those in need of medical treatment. As such, the development of ground-breaking preventive strategies, including innovative diagnostic approaches and therapeutic options, must form an integral component of our ultimate vision. In addition, we must seek to provide the very best education for tomorrow's healthcare workforce and thus stay apace of new trends and possibilities regarding life-long medical education.

In this context, Berlin is emerging as a new global health hub and the Charité can and must take on a pivotal role in these developments. The Charité's recent decision to establish Charité Global Health therefore reflects Germany and Berlin's growing commitment towards tackling global health challenges. Charité Global Health will serve as an interdisciplinary center which coordinates and further develops the Charité's global health portfolio whilst simultaneously fostering increased collaborations with national and international stakeholders. This in turn will augment existing policies and thus influence the larger global health agenda. To achieve these major goals, the Charité already collaborates closely with its academic partners in Berlin, within the M8 Alliance and in a national and international context.

For the tenth consecutive year, the World Health Summit unites experts from across the globe, jointly committed to improving the health of the world's population. We are extremely excited to welcome such an array of excellent minds to Berlin and hope that this year's Summit prove inspiring and fruitful.

Karl M. Quanty

Chief Executive Officer
Charité - Universitätsmedizin Berlin

The Vin

Axel Radlach Pries

Dean

Charité - Universitätsmedizin Berlin



The World Health Summit is one of the world's most prominent strategic forums for global health. The interdisciplinary event takes place within an atmosphere of academic freedom and is the premier international platform for exploring strategic developments and decisions in the area of healthcare.

Facts at a glance

- Annual event in Berlin
- Patronage: German Chancellor Angela Merkel, President of the Republic of France Emmanuel Macron and European Commission President Jean-Claude Juncker
- Mission: Improve health all over the world through collaboration and open dialogue
- Participants: 2,000 from 100 countries
- Founded: 2009 on the 300th anniversary of the founding of the Charité Hospital
- Organized by the WHS Foundation GmbH, a subsidiary of Charité - Universitätsmedizin Berlin

Participants


- Top-level researchers and members of the scientific community
- High-profile political decision-makers
- Executives and representatives from the healthcare system
- Leaders of the health-related industry and technology sector
- Representatives of civil society and foundations
- Students and young professionals from all health-related fields

Website

www.worldhealthsummit.org

Social Media

www.facebook.com/worldhealthsummit www.twitter.com/WorldHealthSmt www.linkedin.com/company/worldhealthsummit/ Hashtag: #WHS2018





VISION AND GOALS

The World Health Summit is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the InterAcademy Partnership (IAP), it is organized in collaboration with national academies of science in 97 countries.

The World Health Summit aims to improve health all over the planet, catalyzing that process through collaboration and open dialogue, and steering tomorrow's agenda to improve research, education, healthcare, and policy outcomes.

It brings together researchers, physicians, key government officials, and representatives from industry as well as from NGOs and healthcare systems all over the world to address the most pressing issues facing every facet of healthcare and medicine in the upcoming decade and beyond.

The World Health Summit is built on the stable foundation of academic excellence provided by the M8 Alliance and has strong political support from a variety of partners at global, national and state levels

MAIN GOALS AND PARTNERSHIP ASSETS

The M8 Alliance is improving global health through pursuit of five strategic goals:

- Bring together all stakeholders at the level of equals
- Establish a unique and sustainable high-level forum and network
- Help define the future of medicine, research and healthcare
- Find answers to major health challenges both today and tomorrow
- Make global recommendations and set health agendas worldwide

Pandemic Preparedness

The ability to prevent, detect, respond to and control outbreaks is a significant investment that many countries are still struggling to make. New financing mechanisms – such as the Pandemic Emergency Financing Facility and WHO's Contingency Fund – are therefore critical to ensuring global health security and saving lives. In this process, domestic financing for preparedness and reliable public health mechanisms pose a key challenge.

The Sustainable Development Goals: Health in All Policies

The SDGs are an indivisible and interdependent set of goals for sustainable development that are inherently linked with the Health in All Policies approach. This approach provides a tool for finding common ground between economic and social development, environmental sustainability and human health. One of the most important challenges for global health in the coming decade will be to develop synergies between a wide range of SDGs and health.

Access to Essential Medicines

Some countries have made substantial progress towards improving access to essential medicines and treatments for fighting HIV/AIDS, malaria and tuberculosis. Even so, access to essential medicines in many parts of the developing world remains inadequate, and new challenges – like access to NCD medicines – have arisen. Recent progress shows that access to essential medicines can be improved through stronger partnerships between governments, pharmaceutical companies, civil society and individual consumers.

Health Systems Strengthening

Although we now have a sophisticated arsenal of interventions and technologies for curing disease and prolonging life, gaps in health outcomes continue to widen. The power of existing interventions is not matched by the capacity of health systems to deliver them to those in greatest need, in a comprehensive way and on an adequate scale. Smart investments have to be the centerpiece of domestic policies and financing.

Antimicrobial Resistance

Antimicrobial resistance is rising to dangerously high levels all over the world and now threatens our ability to treat common infectious diseases. The global crisis reflects the overuse of common antibiotics, as well as a lack of new compound development on the part of pharmaceutical companies to address the challenge. Fresh efforts have been made recently to coordinate efforts, implement new policies and renew research efforts. But major gaps remain.

The Digital Healthcare Revolution

The global population is growing and ageing, and that is having a profound impact on healthcare all over the planet. Meanwhile, new developments in technology are blurring the boundaries between the physical, biological and digital worlds. The goal is now the personalization of medicine – allowing tailored treatments for individual patients based on their unique genetic makeup. This revolution has the potential to provide huge health benefits and empower patients, but it also poses new ethical challenges and could make inequities in healthcare even starker than they are today.



WORLD HEALTH SUMMIT

PRESIDENTS



PRESIDENTS 2018



JOÃO GABRIEL SILVA Rector University of Coimbra Portugal



FERNANDO REGATEIRO Chairman of the Board of Directors Coimbra University Hospitals, Portugal



DETLEV GANTEN Honorary Chairman of the Board Charité Foundation, Germany

FORMER PRESIDENTS



HÉLÈNE BOISJOLY Faculty of Medicine, University of Montreal, Canada



ANTOINE FLAHAULT Director Institute of Global Health, University of Geneva, Switzerland



2015 SHUNICHI FUKUHARA Dean Emeritus School of Public Health, Kyoto University, Japan



2014 JOSÉ OTÁVIO AULER JR. JOHN EU-LI WONG Faculty of Medicine, University of São Paulo, Brazil



2013 Chief Executive Officer National University Health System, Singapore



2012 MICHAEL J. KLAG Former Dean Johns Hopkins Bloomberg School of Public Health, USA



2011 STEVE WESSELINGH Dean Monash University, Melbourne. Australia



2010 STEVEN K. SMITH Pro Rector, Health Imperial College London, United Kingdom



2009 AXEL KAHN Dean Sorbonne Paris Cité. France

CO-CHAIRS



STEFAN KAUFMANN Director Max Planck Institute for Infection Biology, Germany



FERNANDO REGATEIRO Chairman of the Board of Directors Coimbra University Hospitals, Portugal

The World Health Summit Scientific Committee consists of the M8 Alliance Executive Committee (see page 27) and these members of the World Health Summit Council:

MEMBERS



TILL BÄRNIGHAUSEN Director Heidelberg Institute of Public Health, Germany



Nobel Prize Laureate President Emerita Salk Institute for Biological Studies, USA



ELIZABETH BLACKBURN THOMAS B. CUENI Director General International Federation of Pharmaceutical Manufacturers & Associations Switzerland



CHRISTIAN DROSTEN Director, Institute of Virology Charité - Universitätsmedizin Berlin, Germany



BÄRBEL-MARIA KURTH Director, Epidemiology and Health Monitoring Robert Koch Institute, Germany



THOMAS METTENLEITER President Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Germany



MAIKE SANDER Director Pediatric Diabetes Research Center, UC San Diego, USA



GÜNTER STOCK President ALLEA All European Academies, Germany

WORLD HEALTH SUMMIT

AMBASSADORS AND COUNCIL



WORLD HEALTH SUMMIT AMBASSADORS



EDELGARD BULMAHNFormer Federal Minister of Education and Research
Germany



MANFRED DIETEL Director, Comprehensive Cancer Center Charité – Universitätsmedizin Berlin, Germany



ECKART VON HIRSCHHAUSEN Medical Doctor and Cabaret Germany



MICHAEL RABBOW Senior Advisor E&P Focus Africa Consulting, Germany



HEINZ RIEDERER Managing Director iNG innovation. Nachhaltigkeit. Gesundheit, Germany



REINHARD SCHÄFERS Former Ambassador Federal Republic of Germany



ANSGAR TIETMEYER Former Head of Public Affairs Deutsche Bank AG, Germany



CHARLES YANKAH Chairman of the Board Afrika Kulturinstitut e.V., Berlin, Germany

COUNCIL

CHAIR



ILONA KICKBUSCH
The Graduate Institute
of International and
Development Studies,
Switzerland

MEMBERS

ALA ALWAN

University of Washington, Department of Global Health

RIFAT ATUN

Harvard T.H. Chan School of Public Health

TILL BÄRNIGHAUSEN

Heidelberg University

HANS-PETER BAUR

German Federal Ministry for Economic Cooperation and Development

INGO BEHNEL

German Federal Ministry of Health

CHRISTOPH BEIER

Deutsche Gesellschaft für Internationale Zusammenarbeit

CHRISTOPH BENN

The Global Fund to Fight AIDS, Tuberculosis and Malaria

TOBIAS BERGNER

German Federal Foreign Office

ARNAUD BERNAERT

World Economic Forum

CATHERINA BÖHME

Foundation for Innovative New Diagnostics

THOMAS B. CUENI

Int. Federation of Pharmaceutical Manufacturers & Associations

MANFRED DIETEL

Charité - Universitätsmedizin Berlin

KLAUS DUGI

Boehringer Ingelheim GmbH & Co KG

TIMOTHY EVANS

World Bank

ROLAND GÖHDE

German Healthcare Partnership

JÖRG HACKER

German National Academy of Sciences Leopoldina e.V.

ANDREW HAINES

London School of Hygiene & Tropical Medicine

ZSUZSANNA JAKAB

World Health Organization

ASHISH JHA

Harvard Global Health Institute

STEFAN KAUFMANN

Max Planck Institute for Infection Biology

SUSANNA KRÜGER

Save the Children Germany

BÄRBEL KURTH

Robert Koch Institute

STEVE LANDRY

Bill & Melinda Gates Foundation

YVES LEVY

Institut national de la santé et de la recherche médicale

MARION LIESER

Oxfam Germany

KLAUS LINDPAINTNER

King Abdullah International Medical Research Center

LUIZ LOURES

UNAIDS

PHILIPPE MEYER

Descartes University

JÜRGEN MLYNEK

Falling Walls Foundation

MATSHIDISO REBECCA MOETI

World Health Organization

BERND MONTAG

Siemens Healthineers

ANDREAS PENK

Pfizer Germany

HAGEN PFUNDNER

Roche Pharma AG

PETER PIOT

London School of Hygiene and Tropical Medicine

ERICH REINHARDT

Medical Valley

HEINZ RIEDERER

iNG innovation. Nachhaltigkeit. Gesundheit,

MAIKE RÖTTGER

Association Development and Humanitarian Aid

MATHIAS SCHELLER

Albertinen-Diakoniewerk

HANS J. SCHELLNHUBER

Potsdam Institute for Climate Impact Research

GEORG SCHÜTTE

German Federal Ministry of Education and Research

GÜNTER STOCK

ALLEA All European Academies

HEIKO WARNKEN

German Federal Ministry for Economic Cooperation and Development

LOTHAR WIELER

Robert Koch Institute

MISSION



The M8 Alliance's vision is to harness academic excellence to improve global health.

The M8 Alliance of Academic Health Centres, Universities and National Academies is a collaboration between academic institutions committed to improving global health. Working together with political and economic decision-makers, its primary goal is to develop science-based solutions to health challenges all over the world.

This international network is the outstanding academic foundation upon which the World Health Summit - the pre-eminent annual forum for healthcare dialogue - is

built. It functions as a permanent platform for framing the future considerations of global medical developments and health challenges in an equitable fashion.

The M8 Alliance promotes both "bench-to-bedside" translation of research and the transformation of current medical care approaches to treating the ill. It is seeking to accomplish this through the creation of a healthcare system focused on the effective prevention of diseases, as well as the adaptation of health-related solutions to rapidly changing living conditions through research in priority areas like shifting demographics, urbanization and climate.





GOALS



The M8 Alliance is improving global health through pursuit of five strategic goals:

- Developing a worldwide network of academic health science centers, and bringing together universities and healthcare providers;
- Facilitating dialogue through the World Health Summit across a global network of stakeholders who are engaged with academic health science centers. These stakeholders include (among others) individuals and institutions active in government, industry and commerce, inter-governmental agencies, healthcare providers, academies of medicine and science, professional associations and the media;
- Setting an agenda for global health improvement by addressing issues of interest to academic health science centers, and conveying findings and recommendations based on scientific evidence through the generation of key statements;
- Positioning the M8 Alliance as an authoritative, credible and respected influence when it comes to decision-making in global health;
- Creating a knowledge base amongst M8 Alliance members, which directly involves the promotion of mutual learning, research collaboration, the enrichment of educational capabilities and enhanced clinical outcomes.



EXECUTIVE COMMITTEE



JOÃO GABRIEL SILVA Acting International President

Rector, University of Coimbra, Portugal



FERNANDO REGATEIRO Acting International President

Chairman of the Board of Directors, Coimbra University Hospitals, Portugal



DETLEV GANTEN Founding PresidentCharité Foundation,
Germany



ALI JAFARIAN Incoming International President

Chancellor, Tehran University of Medical Sciences, Iran



HÉLÈNE BOISJOLY Past International President

Dean, Faculty of Medicine, University of Montreal, Canada



AXEL RADLACH PRIES Dean of Host Institution Charité - Universitätsmedizin Berlin, Germany



MICHAEL J. KLAG Strategic Co-operation and Stakeholder Liaison Former Dean, Johns Hopkins Bloomberg School of Public Health, Baltimore,

USA



BEN CANNY Governance and Fundraising Head, School of Medicine, University of Tasmania, Australia



JOSÉ OTÁVIO AULER JR.
Officer at large

Dean, Faculty of Medicine, University of São Paulo, Brazil



M8 ALLIANCE HEADS OF DELEGATION

Australia

CHRISTINA MITCHELL

Dean

Monash University, Melbourne

Brazil

JOSÉ OTÁVIO AULER JR.

Dean

Faculty of Medicine, University of São Paulo

EDUARDO KRIEGER

Former President

Brazilian Academy of Sciences

Canada

HÉLÈNE BOISJOLY

Dean

Faculty of Medicine, University of Montreal

TARIK MÖRÖY

President and Scientific Director Clinical Research Institute Montreal (IRCM)

China

XUETAO CAO

President

Chinese Academy of Medical Sciences & Peking Union Medical College

DEPEI LIU

Co-Chair

InterAcademy Partnership (IAP)

France

GÉRARD FRIEDLANDER

Dean

Faculty of Medicine, University of Paris Descartes

FRANÇOIS HOULLIER

Acting President

Université Sorbonne Paris Cité

Germany

KARL MAX EINHÄUPL

Chief Executive Officer

Charité - Universitätsmedizin Berlin

AXEL RADLACH PRIES

Dean

Charité - Universitätsmedizin Berlin

Iran

ALI JAFARIAN

Chancellor

Tehran University of Medical Sciences

AMIRHOSSEIN TAKIAN

Chair and Professor Global Health and Public Policy, Ministry of Health and Medical Education

Italy

EUGENIO GAUDIO

Rector

Sapienza University

LUCIANO SASO

Vice-Rector for European University Networks Sapienza University

Japan

SHUNICHI FUKUHARA

Dean Emeritus

School of Public Health, Kyoto University

Portugal

FERNANDO REGATEIRO

Chairman of the Board of Directors Coimbra University Hospitals

JOÃO GABRIEL SILVA

Rector

University of Coimbra

Russian Federation

IVAN DEDOV

President

Russian Academy of Medical Sciences

EVGENY SIDORENKO

Vice-President Russian Academy of Medical Sciences

Singapore

JOHN EU-LI WONG

Chief Executive Officer

National University Health System Senior Vice-President (Health Affairs), National University of Singapore

KHAY GUAN YEOH

Dean

Yong Loo Lin School of Medicine, National University of Singapore

TEO YIK YIN

Vice-Dean (Research)
Saw Swee Hock School
of Public Health
National University of Singapore

Switzerland

HENRI BOUNAMEAUX

Dean

Faculty of Medicine, University of Geneva

ANTOINE FLAHAULT

Director

Institute of Global Health

ILONA KICKBUSCH

Director

Global Health Program, Graduate Institute

BERTRAND LEVRAT

Chief Executive Officer Geneva University Hospitals

NICOLE ROSSET

Deputy Director,

Geneva University Hospitals (HUG) External Affairs and Executive Management Member

Taiwan

CHANG-CHUAN CHAN

Associate Dean

National Taiwan University

Turkey

MAHMUT AK

Rector

Istanbul University

BAHAÜDDIN ÇOLAKOGLU

Dean

Istanbul University, Faculty of Medicine

Uganda

CHARLES IBINGIRA

Principal

Makerere University

United Kingdom

PETER PIOT

Director

London School of Hygiene & Tropical Medicine

ELIO RIBOLI

Director

School of Public Health, Imperial College London

USA

MICHAEL J. KLAG

Former Dean

Johns Hopkins Bloomberg School of Public Health, Baltimore

ELLEN MACKENZIE

Dean

Johns Hopkins Bloomberg School of Public Health, Baltimore

International

STEVEN L. KANTER

President & CEO

Association of Academic Health Centers (AAHC)

LEONEL VALDIVIA

President

World Federation of Academic Institutions for Global Health (WFAIGH)

Individual Members

RIFAT ATUN


Director

Global Health Systems Cluster, Harvard T.H. Chan School of Public Health, USA

BEN CANNY

Head

School of Medicine, University of Tasmania, Australia



WELCOME TO THE

WORLD HEALTH SUMMIT BERLIN 2018

STARTUP TRACK



The World Health Summit Startup Track highlights outstanding ideas and innovative business concepts that have the potential to revolutionize healthcare and improve Global Health.

Out of 60 applications from 19 countries, the jury has invited 25 Startups to visit the World Health Summit 2018. Attending the World Health Summit provides young entrepreneurs with three days of access to world leaders from science, industry, politics, and civil society to set up future collaborations and get to know potential mentors, investors and board members.

10 of them will pitch their ideas to the jury and the World Health Summit audience on October 15, from 12:45 to 13:45. The winner will be presented in an award ceremony at the World Health Summit Night that evening.

Benefits

- Awarded in a ceremony at the World Health Summit Night
- Special access to the World Health Summit and M8 Alliance network
- Exclusive coaching from FLYING HEALTH, one of the leading company builders for health startups in Germany

Pitch

Monday, October 15, 12:45 Saal 1 | Rudolf Virchow

Award

Monday, October 15, 18:30 Saal 1 | Rudolf Virchow

The winner will be presented with an award at the World Health Summit Night in the evening.

Jury

KAI-UWE BINDSEIL

Berlin Partner

JUTTA KLAUER

Pfizer Germany

TOBIAS KURTH

Charité - Universitätsmedizin Berlin

SHARI LANGEMAK

Physician and Digital Healthcare Expert

MARKUS MÜSCHENICH

Flying Health

THIMO V. SCHMITT-LORD

Bayer Foundations

ANNA BABETTE STIER

German Federal Ministry of Health

ALF WACHSMANN

Max Delbrück Center for Molecular Medicine

UTE E. WEILAND

Deutschland - Land der Ideen (Speaker)

ROLF ZETTL

Berlin Institute of Health



THE 10 FINALISTS

Caspar Health | Germany Business Area: Telemedicine for musculoskeletal conditions www.caspar-health.com

CASPAR

Magnosco GmbH | Germany Business Area: Skin Cancer Detection www.magnosco.com ∷:magnosco

DX-Labtrack | Germany
Business Area:
Blood and Transfusion Safety
www.dx-labtrack.com



Pay It Forward | USA Business Area: STD Testing www.seshglobal.org



Eyeluminati | India Business Area: Health and Wellness, Accessibility www.facebook.com/Manovue-367387056758977/?ref=br rs



SpotSense | India Business Area: Medical Diagnostics www.spotsense.in



ImmunifyMe | Sri Lanka Business Area: Medi Tech www.immunify.me



Strand Therapeutics Inc. | USA Business Area: Cancer Immunotherapeutics www.strandtx.com



inveox GmbH | Germany
Business Area:
Digital Drug / Depression Therapy
www.inveox.com



Wulira App | Uganda Business Area: Health Technology www.wuliraapp.com



NIGHT

Monday, October 15, 18:30 Saal 1 | Rudolf Virchow The World Health Summit Night as the central networking event hosts the award ceremony of the Startup Track.













October 14-16, 2018, 09:00-18:00 In front of Saal 7 | Elizabeth Blackwell

The New Voices in Global Health initiative promotes the active participation of young scientists in the World Health Summit. It is supported by the M8 Alliance of Academic Health Centers, Universities and National Academies. It is aimed at empowering research, policy and advocacy initiatives among future leaders in global health, who are invited to send in abstracts of their scientific work and ideas.

The World Health Summit Scientific Committee (see page 21) identified the best applications based on international academic standards. The selected candidates will be able to display their work in a special poster exhibition, thus playing an active role in the World Health Summit.

The selected New Voices in Global Health are:

Faith Agbozo, Abdulai Abubakari and Albrecht Jahn

Institute of Public Health, Heidelberg University Medical Faculty, Germany

Is there need to reconsider screening procedures for gestational diabetes mellitus at lower level facilities? Evidence from a diagnostic accuracy study

Syeda Akila Ally

University of Chicago

Suicide as a Mental Health Outcome:

A Case Study of South Asia's Mental Health Policy and Infrastructure

Rebecca Racheal Apolot

Makerere University School of Public Health

The Game Changers: Breaking Through Resource Limitation to Ebola Control by Community Structures: The Case of Bombali District -Sierra Leone

Franz Castro

Gorgas Memorial Institute for Health Studies Determinants of under-5 mortality reduction in Central America: a secondary analysis from the GBD Study data

Moyukh Chowdhury

Umeå University

AMR-Watch: A pilot study to initiate Antimicrobial Resistance surveillance system in North-eastern Bangladesh

Kealoha Fox

Office of Hawaiian Affairs

Health in All Policies Legislation that Integrates Cultural Values with State Government Planning

Berit Sofie Hustad Hembre

The Norwegian Institute of Public Health

Access to medicines and structural power: The perceived role of the state and emerging state actors in landmark reports

Connor Rochford

University of Oxford


A One Health Approach to the Global Governance of Antimicrobial Resistance – review of evidence and three possible models

Hannah Thomas

NIHR Unit of Global Surgery (Universities of Birmingham, Edinburgh and Warwick), Clinical Surgery, University of Edinburgh, Edinburgh, UK Safety Processes Undermined During Surgical Emergencies? A Comparison of WHO Surgical Safety Checklist Use and Outcomes in a Large, Multinational Cohort of Surgical Patients

Tran Thu Ngan, Do Van Vuong, Nguyen Tuan Lam, Hoang Van Minh

Hanoi University of Public Health and World Health Organization-Vietnam Office Willingness to participate and pay for smoking cessation service through text-messaging in Vietnam



PROGRAM

SUNDAY, OCTOBER 14

PANEL DISCUSSION

PD 01

SAAL 6 | EUROPE 11:00-12:30

MIGRATION AND REFUGEE HEALTH



HOSTS

M8 Alliance:

University of Montreal



More people are on the move now than ever before. There are an estimated 1 billion migrants in the world today of whom 258 million are international migrants and 763 million internal migrants one in seven of the world's population. 65 million of the world's internal and international migrants are forcibly displaced today. This rapid increase of population movement has important public health implications, and therefore requires an adequate response from the health sector. Challenges to migrant health can be attributed to many factors, including lack of access to health services, absence of financial protection, and discrimination.

Although the number of people seeking refuge is the highest in developing countries, the rapid increase of refugees to Europe over the past two years has altered the political landscape and will have a lasting impact for many years to come. During this politically turbulent time, the health of refugees must continue to be viewed as important to governments worldwide. New strategies and ways to support migrant health must be discussed and based on ratified international human rights standards.

CHAIR

Hélène Boisjoly

University of Montreal | Dean of Medicine | Canada

SPEAKERS

Mina Barling

IPPF The International Planned
Parenthood Federation |
External Relations Division | Director |
United Kingdom

Zsuzsanna Jakab

World Health Organization (WHO) | Regional Director for Europe | Denmark

Susanna Krüger

Save the Children Germany | CEO | Germany

Karlee Silver

Grand Challenges Canada | Programs | Vice President | Canada

Elhadj As Sy

International Federation of the Red Cross (IFRC) | Secretary General | Switzerland



Mina Barling



Susanna Krüger



Hélène Boisjoly

Karlee Silver



Zsuzsanna Jakab

Elhadj As Sy

WS 01

SAAL 10 | ASIA 11:00-12:30

FOOD SYSTEMS, NUTRITION AND HEALTH







HOSTS

M8 Alliance: InterAcademy

InterAcademy Partnership (IAP)

Malnutrition in its various forms is a problem faced by all countries. Major challenges for delivering food and nutrition security are compounded by pressures of a growing population, urbanization, climate change, inequality and market instability. The Sustainable Development Goals provide a key framework for addressing the challenges of malnutrition and they mandate fresh engagement by science to resolve complexities of evidence-based policies and programs.

The InterAcademy Partnership project initiated four regional working groups in Africa (NASAC), Asia (AASSA), the Americas (IANAS) and Europe (EASAC) to explore scientific opportunities for sustainable production and healthy diets. The integrative food systems approach included all the steps involved from growing through to processing, trans-

M8 Alliance:

German National Academy of Sciences Leopoldina e.V.

porting, trading, purchasing and consuming food, examining issues for resource efficiency, environmental sustainability, resilience and the public health agenda, while also taking account of local-global interconnectedness of systems.

The published four regional reports are being discussed with national and regional policy makers and are also serving as a collective resource to prepare a fifth, global report. In this session we will discuss some of the emerging regional and global conclusions for food and nutrition security with particular regard to the linkages to health and wellbeing. We emphasize that it is vital to be more ambitious in identifying scientific opportunities and in mobilizing the resource from research and innovation in engagement between the scientific community, policy makers and other stakeholders

CHAIRS

Jörg Hacker

German National Academy of Sciences Leopoldina | President | Germany

Volker ter Meulen

InterAcademy Partnership (IAP) | President

SPEAKERS

Volker ter Meulen

InterAcademy Partnership (IAP) | President Introduction to the Project

Robin Fears

European Academies Science Advisory Council | Bioscience Programme Secretary | United Kingdom Perspectives in Europe

Mohamed H.A. Hassan

Sudanese National Academy of Science | Executive Committee | Sudan Perspectives in Africa

Joachim von Braun

Rheinische Friedrich-Wilhelms-University Bonn | Center for Development Research | Director | Germany Global Analysis and Synthesis of Issues

Jörg Hacker

German National Academy of Sciences Leopoldina | President | Germany Closing Remarks



Robin Fears

Volker ter Meulen



Jörg Hacker

Joachim von Braun



Mohamed H.A. Hassan

WS 02

SAAL 2 | AMERICA 11:00 - 12:30

OPTIMIZING HEALTH IN AGING SOCIETIES



HOSTS

University of Rostock

M8 Alliance:

Kyoto University

M8 Alliance:

National Taiwan University (NTU)

Max Planck Society









Below-replacement fertility and rising life expectancy primarily due to survival improvements among people at advanced ages lead to population aging in many parts of the world. This continuously increasing proportion of the elderly requires new strategies in virtually every field of public policy, probably most prominently for health care.

The workshop seeks to provide a framework for potential pathways for health developments, starting with a presentation of recent research on mortality among the elderly.

The focus in the subsequent presentations and discussions of this workshop will be on populations that are at the forefront of aging: Japan, East Asia as well as the Nordic European countries.

What health trends can we observe and how are societies dealing with current and future challenges to health care are only two questions that will be addressed throughout the workshop

45

CHAIRS

Roland Rau

University of Rostock | Professor of Demography | Germany Max Planck Institute for Demographic Research | Fellow | Germany

Shunichi Fukuhara

Kyoto University | School of Public Health | Dean Emeritus | Japan



Elisabetta Barbi

Jun Miyashita

SPEAKERS

Elisabetta Barbi

Sapienza University of Rome | Associate Professor of Demography | Italy

The Plateau of Human Mortality

Shou-Hsia Cheng

National Taiwan University | College of Public Health | Professor and Associate Dean | Taiwan The Performance of Hospital Care for the Elderly in Asian Countries: The Case of Hip Fracture Surgery

Jun Miyashita

Kyoto University Graduate School of Medicine | Assistant Professor of Medicine | Japan

Who Desires Early Advance Care Planning? Strategies for Having a Good End of Life in Aging Societies

Karin Modig

Karolinska Institutet | Institute of Environmental Medicine | Assistant Professor | Sweden

Health of the Ageing Population – Time Trends, Current Status and Future Perspectives. Examples from the Nordic Countries



Shou-Hsia Cheng

Karin Modig



Shunichi Fukuhara

Roland Rau

WS 03

SAAL 4 | AFRICA 11:00 - 12:30

BRIDGING THE VALLEY OF DEATH

Keeping the Pipeline Alive for Novel Intervention Measures Against Poverty-Related Diseases



HOSTS

European and Developing Countries Clinical Trials Partnership (EDCTP)

Foundation for Innovative New Diagnostics (FIND)

Max Planck Society





Although infectious diseases remain a major health threat, the pipeline for novel intervention measures has come to a standstill. The situation has been further worsened by the profound increase of antimicrobial resistant pathogens and increasing occurrence of outbreaks with pandemic risk.

Hence, better vaccines, drugs and diagnostics are urgently needed. This is particularly true for poverty-related diseases (PRDs) including the Big Three:

tuberculosis, HIV/AIDS and malaria, and neglected diseases. It has become obvious that public and private funded institutions need to form partnerships to accelerate this process.

This workshop will discuss general strategies for, and more specific examples, of the clinical development of novel intervention measures and their optimization to key populations, aimed at accomplishing this goal with a particular focus on PRDs.

CHAIRS

Stefan H.E. Kaufmann

Max Planck Institute for Infection Biology Department of Immunology | Director | Germany

Michael Makanga

European and Developing Countries Clinical Trials Partnership (EDCTP) Executive Director | Netherlands





Catharina Boehme



Gérard Krause

SPEAKERS

Catharina Boehme

Foundation for Innovative New Diagnostics (FIND) | CEO | Switzerland Overcoming the 2 Valleys of Death in **Infectious Diseases Diagnostics**

Ambassador Harald Braun

Germany's former Permanent Representative to the United Nations Latest News from the UN General Assembly First-Ever High-level Meeting on Ending Tuberculosis (TB)

Mutsa Bwakura-Dangarembizi

University of Zimbabwe | Department of Paediatrics and Child Health | Senior Lecturer | 7imbabwe **HIV Treatment in Children**

Gérard Krause

Helmholtz Centre for Infection Research (HZI) | Department for Epidemiology | Head | Germany

The Need for an Integrated Surveillance **Outbreak Response Management and Analysis System (SORMAS)**

Michael Makanga

European and Developing Countries Clinical Trials Partnership (EDCTP) Executive Director | Netherlands The Role of EDCTP in PRDs

Umesh Shaligram

Research & Development

Serum Institute of India Pvt 1 td 1 Director Research & Development | India Companies, Vaccines and a Novel TB Vaccine

Feiko ter Kuile

Liverpool School of Tropical Medicine | Chair in Tropical Epidemiology | United Kingdom

Challenges and Progress in the Treatment and Prevention of Malaria in Pregnancy



Harald Braun

Michael Makanga



Mutsa Bwakura-Dangarembizi



Umesh Shaligram



Stefan H.E. Kaufmann

Feiko ter Kuile

WS 04

SAAL 5 | OCEANIA 11:00 - 12:30



BUILDING THE FUTURE OF



HOST

European Commission

The healthcare sector is the largest economic sector in the EU. Health is also one of the most important concerns of European citizens.

Europe leads in many areas of research and has developed powerful models of cross-border, cross-sectoral research cooperation. These have helped to increase the EU's attractiveness as a place for research and innovation, produced high-quality patents and created jobs and growth. However, innovation in health is characterized by a unique set of challenges, such as the multifaceted interaction between research, innovation. patient care and population health and complex regulatory and reimbursement systems. At the same time, advances in precision medicine and the use of health data create a wealth of opportunities.

In order for innovation to occur and become available and accessible to all European citizens in an equitable manner, governance and management of public investment in health research need to be impact and patient oriented, inclusive and holistic

The Scientific Panel for Health, one of the expert groups tasked by the Commission, has proposed the creation of a European Council for Health Research to fulfill the above criteria. The session will compare different international models of organizing public investment in health research and focus on the impact on public health and health care

CHAIR

Karin R. Sipido

European Commission | Scientific Panel for Health | Chair | Belgium

SPEAKERS

Ildikó Horváth

Semmelweis University | Department of Pulmonology | Professor | Hungary

Anna Lönnroth Sjöden

European Commission | Directorate-General for Research and Innovation | Directorate E-Health | Unit 1 - Strategy | Head of Unit | Belgium

Bernd Stowasser

Sanofi | Global Head of Public Private Partnerships Alliance Management | Germany

European Federation of Pharmaceutical Industries and Associations (EFPIA) | Member of Innovative Medicines working group | Germany

Mats Ulfendahl

Regional Council of Östergötland | Director of Research | Sweden

DISCUSSANTS

Laurent Degos

Institut Pasteur | Vice-President | France

Tarik Möröy

Institut de Recherches Cliniques de Montréal (IRCM) | President and Scientific Director | Canada

Axel Radlach Pries

Charité - Universitätsmedizin Berlin | Dean | Germany



Ildikó Horváth

Karin R. Sipido



Tarik Möröy

Bernd Stowasser



Axel Radlach Pries

Mats Ulfendahl



Anna Lönnroth Sjöden

PANEL DISCUSSION

PD 02

SAAL 6 | EUROPE 14:00-15:30

MANAGING THE NEXT DECADE IN CANCER

Innovation meets Growing Inequalities



HOSTS

International Prevention Research Institute (iPRI)

Pfizer



In the next decade medical progress in treating cancer will potentially redefine life with this disease. Upcoming innovations will improve the treatment in many cancers. Further, better understanding and new forms of research due to e.g. "Big Data" will make us know "which drugs to give to which patients" and which treatment will be most effective and best for patients. The health care systems will have to meet the challenge to ensure fast access to these innovations: By 2030, the global burden of cancer is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths simply due to the growth and aging of the population.

But recent OECD publications show a growing inequality around the world -

the drivers are globalization, skill-biased technological change and changes in countries' policy approaches. Inequalities in health status are due to many factors, including differences in living and working conditions and in behavioral factors, but also in access to and quality of health care. Despite significant progress in most countries, access to quality health care varies across the socio-demographic groups, including by sex, age, geographic area and for financial and non-financial reasons.

These growing inequalities lead to a poor translation of innovation in cancer care into health care systems in diverse communities, it hampers the impact of innovative treatments and precision medicine advances.

CHAIRS

Andreas Penk

Pfizer Germany GmbH | Oncology | Regional President | Germany

Peter Boyle

International Prevention Research Institute (iPRI) | President | France

SPEAKERS

Peter Boyle

International Prevention Research Institute (iPRI) | President | France

Richard Sullivan

King's College London | Institute of Cancer Policy | Director | United Kingdom

Julie S. Torode

Union for International Cancer Control (UICC) | Director of Special Projects | Switzerland

Sabine Vogler

Gesundheit Österreich GmbH | WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies | Head | Austria

Dazhu Yang

International Atomic Energy Agency | Deputy Director General



Peter Boyle

Julie S. Torode




Andreas Penk

Sabine Vogler



Richard Sullivan



Dazhu Yang

WS 05

SAAL 10 | ASIA 14:00-15:30





WGH

HOSTS

Research in Gender Ethics (RinGs)

Women in Global Health

This workshop will utilize didactic and interactive learning techniques. Key representatives from Women in Global Health, RinGs and the Global Health Workforce Network Gender Equity Hub will present key findings on the barriers, as well as solutions to gender transformative health systems policies. The panelists will draw from key findings in the working paper being developed by the Gender Equity Hub, as well as panelists' own work and research.

Following the initial presentations, audience members will be engaged in breakout sessions. These breakout sessions will be interactive dialogues where facilitators will lead participants through exercises on how to implement gender transformative policies for the health workforce and in turn how to address the gendered dimensions of health systems strengthening.

CHAIR

Roopa Dhatt

Women in Global Health | Initiative Director & Co-Founder | United States of America

SPEAKERS

Evelyn Kabia

KEMRI-Wellcome Trust | Health Economics Research Unit | Assistant Research Officer | Kenya

Rosemary Morgan

Johns Hopkins Bloomberg School of Public Health | International Health | Assistant Scientist | United States of America

Christina Schrade

SEEK Development | Managing Director | Germany

Kelly Thompson

Women in Global Health | Gender Specialist | United States of America







Christina Schrade



Evelyn Kabia



Kelly Thompson



Rosemary Morgan

WS 06

SAAL 2 | AMERICA 14:00 - 3:30

SOCIAL STRESS, INEQUALITY AND MENTAL HEALTH IN CITIES







HOSTS

Fliedner Klinik Berlin

M8 Alliance:

Charité - Universitätsmedizin Berlin

Urbanization is one of the most significant global changes with an enormous health impact within the next decades. According to the United Nations projections two-thirds of the urban population will be living in cities. At the same time city living and urban upbringing can affect the mental health of urban dwellers through social stressors and subsequently increase the risk for mental-ill health. Social stress in urban environments may result from high social density and overcrowding, social isolation and excessive within-city inequality. Identifying populations who are particularly at risk for social stress in urban environments and who do not have adequate access to the urban advantage seems therefore key.

However, cities keep attracting people as they promise improved standards of living,

better access to education, wealth, sanitation and health care and offer a broader cultural diversity. Health researchers, urban planners and governmental authorities have largely failed to develop public mental health strategies for the growing cities in all parts of our world. Such a strategy should particularly address at-risk populations with their increased exposure to urban stressors and recommend strategies to facilitate overall access to the urban advantage.

This workshop will identify the major health-relevant social stressors and at-risk populations for stress-dependent mental-ill health, and discuss approaches towards a public mental health strategy for urban environments.

CHAIR

Mazda Adli

Fliedner Klinik Berlin | Chair | Germany Charité - Universitätsmedizin Berlin | Mood Disorder Research Group | Director | Germany

SPEAKERS

Carlos Dora

World Health Organization (WHO) | Department of Public Health and Environment | Coordinator | Switzerland

Ulrike Kluge

Charité Universitätsmedizin Berlin | Department of Psychiatry and Psychotherapy | Intercultural Center for Psychiatry and Psychotherapy (ZIPP) | Director | Germany

Faraaz Mahomed

Open Society Foundations | Mental Health and Rights | Program Officer | United States of America

François Pelletier

United Nations | Department of Economic and Social Affairs (DESA) | Chief of Population Estimates and Projections Section | United States of America

Sahar Samavati

Tarbiat Modares University | Iran



Mazda Adli



Faraaz Mahomed



Carlos Dora



François Pelletier



Ulrike Kluge



Sahar Samavati

WS 07

SAAL 4 | AFRICA 14:00-15:30

INTERNATIONAL LIFE SCIENCES LOCATION AND INFRASTRUCTURE MANAGEMENT

Best Practices from Around the World



HOSTS

Ministry of Economic Affairs Canton of Bern

M8 Alliance



In the context of the World Health Summit 2018, the Ministry of Economic Affairs of the Canton of Bern, Switzerland, will host a workshop on the topic of "International Life Sciences Location and Infrastructure Management: Best Practices from Around the World".

The fact that a Ministry of Economic Affairs puts this health policy issue at the center of attention is an important strategy of the Canton of Bern. We believe that the conventional, more or less strictly differentiation of responsibilities by department (economy, science, health, finance, etc.) is in some fields not enough result-oriented

and must be overcome, if the overall goal is to provide medicine and medical research as a central driver of social change and as a backbone of health-oriented developed societies. The location strategy for medicine and medical research, which the Canton of Bern and the Swiss capital region advances nationally and internationally, therefore follows the guiding principle "Health in All Policies", surely also in regional economic policy. The new medical and health Campus in Bern is of national importance. All political forces are brought together to raise successfully an open-oscillating functional system of research, translational medicine and care.

CHAIRS

Ralph Kray

Canton of Bern | Ministry of Economic Affairs | Head of International Affairs | Switzerland

André Nietlisbach

Canton of Bern | Ministry of Economic Affairs | Secretary General | Switzerland

SPEAKERS

Barkin Arak

Boğaziçi University | Technology Transfer Office | Entrepreneurship & Innovation Manager | Turkey

Timuçin Bilgör

BUMED Business Angels
(BUBA) | President | Turkey

José Otávio Costa Auler Jr.

University of São Paulo | Faculty of Medicine | Dean | Brazil

Uwe Jocham

Insel Gruppe AG | CEO and Chairman of the Board of Directors | Switzerland

Fabian Käsermann

CSL Behring AG | Associate Director & Head of Preclinical Innovation | Switzerland

Depei Liu

Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC) | Former President | China Chinese Academy of Engineering | Former Vice-President | China

Richard B. Markham

Johns Hopkins Bloomberg School of Public Health | Molecular Microbiology and Immunology | Faculty Director | United States of America

Fernando J. Regateiro

Coimbra Hospital and University Centre (CHUC) | Administration Board | Chairman | Portugal



Peter Agre



Uwe Jocham



Richard B. Markham



Barkin Arak



Fabian Käsermann



André Nietlisbach



José Otávio Costa Auler Jr.



Ralph Kray



Fernando J. Regateiro

DISCUSSANTS

Peter Agre

Johns Hopkins Bloomberg School of Public Health | Johns Hopkins Malaria Research Institute | Director | United States of America

Ozan Alptekin

BiSU | CTO | Turkey

Ersen Kavak

Genomize Inc. | CEO | Turkey

Ihsan Solaroglu

Koç University | School of Medicine | Associate Dean for Research | Turkey



Timuçin Bilgör



Depei Liu

WS 08

SAAL 5 | OCEANIA 14:00 - 15:30



The Use of Digital to Improve Patient Outcome from Research to Real World



M8 Alliance:

HOSTS

Charité - Universitätsmedizin Berlin

Sanofi





Collecting and analyzing the increasing amount of data from patients' daily life is essential for improving care management. While the generation, integration and analyses of data from real life, randomized clinical trials, electronic medical records and public data is opening new ways for future treatments, the active involvement of all stakeholders (patients, physicians and the pharmaceutical industry but also regulators, payers and public health officials) remains essential if we

want to build a new frame for healthcare innovation and evaluation.

This panel aims to focus on the opportunities afforded by incorporating concepts like Big Data, digital health, machine learning, and artificial intelligence (AI) and understand how to lift through a concerted effort between the various parts of the healthcare ecosystem, the challenges and obstacles which remain.

CHAIRS

Stefan Willich

Charité Universitätsmedizin Berlin | Institute for Social Medicine, Epidemiology and Health Economics | Director | Germany

Bernard Hamelin

Sanofi | Global Head of Medical Evidence Generation | France



Nikolai Brun

Alex Silverstein

SPEAKERS

Nikolai Brun

Danish Medicines Agency | Medical Evaluation & Biostatistics | Director of Division | Denmark

Laurent Doyen

French Diabetes Federation | Member of the Board of Directors | France

Bernard Hamelin

Sanofi | Global Head of Medical Evidence Generation | France

Alex Silverstein

NHS North West London Collaborative of Clinical Commissioning Groups | Diabetes Education and Engagement Lead | United Kingdom

Bernhard Tilg

Member of the Provincial Government of Tyrol | Austria



Laurent Doyen

Bernhard Tilg



Bernard Hamelin

Stefan Willich

PANEL DISCUSSION

PD 03

SAAL 6 | EUROPE 16:00-17:30

AN INTEGRATED RESPONSE TO OBESITY, DIABETES, AND NCDS

Opportunities to Accelerate National Action



NCD Alliance



HOSTS

Sanofi

The NCD Alliance

NCDs) as WHO's Post [

Noncommunicable diseases (NCDs) are now widely recognized as a major challenge to health and sustainable human development in the 21st century. As the leading cause of death and disability worldwide, NCDs exact a heavy and growing toll on the health and economic security of all countries and disproportionately impact the most vulnerable in particular in low- and middle-income countries. Without coordinated action at the highest political level, the escalating burden and cost of NCDs will weigh heavy across all pillars of sustainable development.

NCD investments, similar to investments in communicable diseases, antimicrobial resistance, maternal and child health and climate change, are investments in countries' futures. Premature mortality and disability due to NCDs are largely preventable and cost-effective solutions,

e.g. WHO's Best Buys for prevention and control, are available to all Member States. However, weak high-level political action and chronically inadequate investment has hampered progress so far. Out of the 194 countries featured in the 2017 WHO Progress Monitor on NCDs, only 90 have guidelines for the management of major NCDs, which is an essential first step towards provision of effective care.

World Health Organization (WHO)

The 2018 UN High-Level Meeting on NCDs (UN HLM) constitutes a major opportunity to elevate the challenge of implementing effective national responses and international cooperation on NCD prevention and control to the level of Heads of State and Heads of Government. It is time world leaders act and invest in NCDs to avoid preventable death and disability, protect human dignity and the right to health, fight poverty and social inequality and ensure sustained human development.

Objectives:

- To discuss the outcomes of the 2018 UN High-Level Meeting for greater action on NCDs, with a focus on obesity and diabetes;
- To explore opportunities to replicate evidence-based practices for NCD
- prevention and control and promote solutions for integrated healthcare delivery at national and regional levels;
- To present relevant approaches and successful examples to strengthen multistakeholder action on NCDs.



Svetlana Akselrod

Anders Nordström



Bagher Larijani

Edward Omete



Bente Mikkelsen

Gerald Yonga

CHAIR

Bente Mikkelsen

World Health Organization (WHO) | Division of Noncommunicable Diseases and Promoting Health through the Life-course | Director | Denmark

SPEAKERS

Svetlana Akselrod

World Health Organization (WHO) | Noncommunicable Diseases and Mental Health | Assistant Director-General | Switzerland

Bagher Larijani

Ministry of Health and Medical Education | Vice Minister of Education, Council of Medical Education & Speciality Training | Iran

Bente Mikkelsen

World Health Organization (WHO) | Division of Noncommunicable Diseases and Promoting Health through the Life-course | Director | Denmark

Anders Nordström

Ministry for Foreign Affairs | UN Policy Department | Ambassador for Global Health | Sweden

Edward Omete

PharmAccess Foundation | Medical Advisor | Kenya

Gerald Yonga

East Africa NCD Alliance | Chair | Kenya

WS 09

SAAL 10 | ASIA 16:00-17:30



Linking Cultural Heritage, Values, Cutting-Edge Science, Religion, and Health to Promote Peace and Respect



ParD
International Partnership on
eligion and Sustainable Development



HOSTS

M8 Alliance:

InterAcademy Partnership (IAP)

International Partnership on Religion and Sustainable Development (PaRD)

Sustaining peace is the central aim of Sustainable Development Goal (SDG) 16: Peace, justice and strong institutions, and a necessary basis for all other SDGs, including "Good Health and Well-being". Recognizing universal human rights and fundamental freedoms of others is vital to ensure open dialogues as well as the wellbeing and the survival of diverse communities around the globe, as emphasized in the UNESCO's 1995 Declaration on Tolerance.

Against the backdrop of growing violent extremism, conflicts and suffering worldwide, the InterAcademy Partnership (IAP) intends to give science a stronger voice and take more responsibility. Jointly with other organizations, IAP is setting up the initiative "Respect and Dialogue" in order to foster an atmosphere of mutual respect, contribute to an open, free, peaceful, for-

ward-looking enlightened culture of discussion and curtail religious, ideological, political and cultural bigotry. To that end, the IAP member academies will join forces with other groups towards this important goal, including museums and symbolic places of cultural respect and exchange (e.g. the Humboldt Forum in Berlin, the Bibliotheca Alexandrina, the Louvre Abu Dhabi), international policy and academic networks such as "The Science Bridge" and the "Sapiens 5.0" project and global multi-stakeholder-partnerships such as the International Partnership on Religion and Sustainable Development (PaRD). Thus, they will bring together leading experts and practitioners from science. policy, religion, business and media for dialogues about respect, dignity, and nonviolence in different spheres of life around the globe.

The session will explore the relationships between values, cutting-edge science, religion, and health, and look into innovative and unconventional partnerships to investigate how science can contribute more efficiently to promoting respect and peace through an enlightened culture of structured dialogues.

CHAIRS

Edelgard Bulmahn

German Bundestag | former German Federal Minister of Education and Research and former Vice President of the German Bundestag | Germany

Jeremy Farrar

Wellcome Trust | Director | United Kingdom

SPEAKERS

Marwa ElWakil

Library of Alexandria | Head of Academic Research Sector | Egypt

Mohamed H.A. Hassan

Sudanese National Academy of Science | Executive Committee | Sudan

Azza Karam

United Nations Population Fund
(UNFPA) | Senior Advisor |
United States of America
UN Inter-Agency Task Force on Religion
and Development | Coordinator

Rev'd Phumzile Mabizela

Inerela+ | Executive Director | South Africa

Xiaochun Sun

University of Chinese Academy of Sciences | Professor and Acting Dean of School of Humanities | China

Paul Verschure

Universitat Pompeu Fabra | Research Professor & Coordinator Sapiens 5.0 | Spain

DISCUSSANTS

A selected round of experts



Edelgard Bulmahn

Azza Karam



Marwa ElWakil



Rev'd Phumzile Mabizela



Jeremy Farrar



Xiaochun Sun



Mohamed H.A. Hassan



Paul Verschure

WS 10

SAAL 2 | AMERICA 16:00-17:30



Imperial College London





ENSURING PATIENT SAFETY IN HOSPITAL MANAGEMENT

HOSTS

M8 Alliance:

Charité - Universitätsmedizin Berlin

M8 Alliance:

Imperial College London

M8 Alliance:

National University of Singapore (NUS)

During the last 20 years knowledge about patient safety has grown rapidly and measures taken to avoid harm are numerous and widespread - however avoidable adverse events in healthcare are still a worldwide problem.

Research has shown that safety culture and the success of patient safety measures are dependent on the leadership of an organization. Patient safety needs to be approached top-down rather than bottom-up.

In this workshop, we would like to present policies, methods and measures that enhance the involvement of the senior hospital management concerning safety culture and patient safety projects.

Following questions will be discussed:

- How do head of departments learn from adverse events or near misses and how do they facilitate learning from these events?
- Does senior hospital management understand and apply the human factors approach to decisions made at the top level?
- How can Ministries of Health foster a patient safety climate and ensure implementation of risk reduction strategies after serious adverse events?

CHAIR

Ulrich Frei

Charité - Universitätsmedizin Berlin | Medical Director | Germany

SPEAKERS

Mike Durkin

Imperial College London | Institute of Global Health Innovation | Centre for Health Policy | Professor & Senior Advisor on Patient Safety Policy and Leadership | United Kingdom

Felicia Hong

Ministry of Health (MOH) | Assistant Director of the Patient Safety and Quality Improvement Branch | Singapore

Sandhya Mujumdar

National University Hospital Singapore (NUHS) | Deputy Director of Q&S | Singapore

Roland Staudinger

VAMED Management und Service GmbH | Vice President International Hospital Management | Austria



Mike Durkin



Sandhya Mujumdar



Ulrich Frei



Roland Staudinger



Felicia Hong

WS 11

SAAL 4 | AFRICA 16:00-17:30



FALSIFIED AND SUB-STANDARD MEDICINE

Initiatives and Activities to Secure Access to High Quality Medicines

HOST

Association of Research-based Pharmaceutical Companies (vfa)

Marketing and distribution of falsified and substandard medication is a global problem, endangering the appropriate treatment of patients, putting their health and life at risk. Globally, it is estimated that about ten percent of all traded medication is falsified or substandard, in some regions the situation is much worse. There is a need to detect falsified and substandard drugs and eliminate them from pharma markets to protect patients and to secure therapy success.

This session aims at analyzing the scope of the global problem of falsified and substandard drugs, and to demonstrate and discuss practical and locally appropriate options to reduce the risk of fake and substandard drugs entering markets, and measures to detect and eliminate them

MODERATOR

Monika Jones

Moderator & Presenter | Germany & United Kingdom

SPEAKERS

Stefan Artlich

Bayer AG | Track & Trace | Director | Germany

Practical Measures to Minimize the Risk of Falsified Drugs in the Supply Chain

Diana Lee

World Health Organization (WHO) |
Substandard and Falsified Medical
Products | Technical Officer | Switzerland
The World Health Organization
Perspective on Substandard and
Falsified Medical Products

Richard Neci

DCMP 8ème CEPAC | Pharmacist Director | Congo Insights into the Situation of Falsified and Substandard Drugs in Africa

Gisela Schneider

German Medical Mission Institute (DIFAEM) | Director | Germany Civil Society's Experience with Falsified and Substandard Drugs

Han Steutel

Association of Research-based Pharmaceutical Companies (vfa) | Chairman of the Board | Germany Cooperation - Key in the Fight Against Falsified and Substandard Drugs







Richard Neci



Monika Jones

Gisela Schneider



Diana Lee



WS 12

SAAL 5 | OCEANIA 16:00 - 17:30

PREVENTING DEMENTIA BY PREVENTING STROKE









HOSTS

Charité - Universitätsmedizin Berlin

M8 Alliance

World Dementia Council (WDC)

World Stroke Organization (WSO)

Worldwide, stroke and dementia account for 2/3 of disability adjusted life years (DALY). Rates are declining in developed countries and rising in developing ones, suggesting that the control of the common risk factors can affect the incidence of both. A stroke doubles the chances of developing dementia. A successful population level stroke strategy was associated with a 32% decrease in the incidence of stroke and a 7% decrease in the incidence of dementia

Stroke (cerebral infarction) represents a compressed form of neurodegeneration that can cause or trigger dementia. The common mechanisms offer new therapeutic opportunities for treating both

The World Dementia Council includes a platform for risk reduction of the common treatable risk factors underpinning stroke and dementia

In principle, 90% of strokes are preventable and about 30% of dementias. If those developing dementia after a stroke are included, then about 50% of all dementia could be prevented beginning right now. Multimodal interventions have resulted in improvement in cognitive performance, anticoagulants cut the risk of dementia in atrial fibrillation in half, and a growing list of potential treatments await translation from promise into action.

CHAIRS

Karl Max Einhäupl

Charité - Universitätsmedizin Berlin | CEO | Germany

Vladimir Hachinski

World Stroke Organization Joint Prevention of Stroke and Dementia Chair | Canada

Pierluigi Nicotera

German Center for Neurodegenerative Diseases (DZNE) | Director | Germany



Suvarna Alladi

Zaven Khachaturian



Karl Max Einhäupl



Pierluiai Nicotera





Vladimir Hachinski

Brian H. Rowe

SPEAKERS

Suvarna Alladi

University of Cambridge | National Institute of Mental Health and Neuro Sciences (NIMHANS) | Professor | India

Diverging Trends in Stroke and Dementia: Prevention Opportunities

Vladimir Hachinski

World Stroke Organization | Joint Prevention of Stroke and Dementia Chair | Canada

Preventing Dementia by Preventing Stroke: The Bases for Action

Zaven Khachaturian

Campaign to Prevent Alzheimer's Disease by 2020 | President | United States of America Stroke as a Form and a Trigger of Neurodegeneration

Brian H. Rowe

Stroke and Dementia

University of Alberta | Institute of Circulatory and Respiratory Health | Scientific Director | Canada Canadian Initiatives on

KEYNOTE

KEY 01

SAAL 1 RUDOLF VIRCHOW 18:00-19:30

OPENING CEREMONY



HOST

M8 Alliance

World Health Summit Trailer produced by the Deutsche Welle

CHAIRS

Detley Ganten

World Health Summit | President | Germany

Fernando J. Regateiro

Coimbra Hospital and University Centre (CHUC) | Administration Board | Chairman | Portugal

João Gabriel Silva

Coimbra Hospital and University Centre (CHUC) | Dean | Portugal



The World Doctors Orchestra perfoms Ludwig van Beethoven (1770 - 1827) Symphony No.8 in F Major, op.93 Conductor: Stefan Willich

SPEAKERS

Jens Spahn

Ministry of Health (BMG) | Minister of Health | Germany

Elizabeth Blackburn

Salk Institute for Biological Studies | President Emerita | United States of America

Alexander Gerst

German European Space Agency | Astronaut

Albert Bourla

Pfizer Inc. | COO | United States of America

Gerd Müller

Ministry for Economic Cooperation and Development (BMZ) | Minister for **Economic Cooperation** and Development | Germany

Stefan Oschmann

European Federation of Pharmaceutical Industries and Associations (EFPIA) | President | Belgium Merck KGaA | Executive Board | CEO and Chairman | Germany

Matshidiso Rebecca Moeti

World Health Organization (WHO) | WHO Regional Office for Africa | Regional Director for Africa | Congo

Young Leader in Global Health



Detley Ganten



Jens Spahn



Stefan Oschmann

Müller



Elizabeth Blackburn



João Gabriel Silva

Regateiro




Alexander Gerst





Albert Bourla



PROGRAM

MONDAY, OCTOBER 15

PANEL DISCUSSION

PD 04

SAAL 6 | EUROPE 9:00-10:30

GLOBAL HEALTH SECURITY

Munich Security **SE**Conference **Münchner** Sicherheitskonferenz

HOST

Munich Security Conference (MSC)

In recent years, global health security has received increased attention. The Ebola outbreak brought attention to the weaknesses in the systems of preparedness and response. In order to deal with these gaps a number of steps were taken. WHO has committed to improve its emergencies program, while private initiatives have also been developed. Regional organizations such as the EU and the African Union have increased their resolve to address global health security challenges.

Yet despite these initiatives, the world is not ready for the next pandemic. Furthermore, some low-income countries perceive the health security agenda as a device for protecting the developed world from health threats arising from the under-developed world, thereby only advancing the interests of the West.

There is much work to be done in gaining universal acceptance of the global health security agenda and improving collaboration between international, regional and national actors.

However, health security involves more than just infectious disease outbreaks. Health security is also part of wider health systems strengthening and Universal Health Coverage activities, but it is not yet clear how to best synergize these overlapping areas.

Improving global health security is first and foremost a political endeavor. More commitment is required from beyond ministries of health; heads of state across the globe must prioritize health as a political and security issue as well as a medical one.

Wolfgang Ischinger

Munich Security Conference (MSC) | Chairman | Germany

SPEAKERS

Seyyed Hassan Ghazizadeh Hashemi

Ministry of Health and Medical Education | Minister | Iran

Peter Albiez

Pfizer Germany GmbH | CEO | Germany

Seth Berkley

Gavi, The Vaccine Alliance | CEO | Switzerland

Christian Drosten

Charité - Universitätsmedizin Berlin | Institute of Virology Campus Charité Mitte | Director | Germany Charité Global Health, Scientific Director

Jaak Peeters

Johnson & Johnson Global Public Health | Global Head | Germany

BT Slingsby

Global Health Innovative Technology Fund (GHIT) | Executive Director and CEO | Japan

Charlotte Watts

Department of International Development (DFID) | Chief Scientific Adviser | United Kingdom



Peter Albiez

Wolfgang Ischinger



Seth Berkley



Jaak Peeters



Christian Drosten



BT Slingsby



Seyyed Hassan Ghazizadeh Hashemi



Charlotte Watts

WS 13

SAAL 10 | ASIA 9:00-10:30

GROWTH & RESILIENCE

Changing the Paradigm to Save Mothers and Children

BILL & MELINDA GATES foundation

Grand Challenges

HOSTS

Bill & Melinda Gates Foundation

Grand Challenges

We have made impressive progress in maternal, newborn and child survival in the last decade and a half. However, the burden continues to become more complex, and to meet the targets laid out in the Sustainable Development Goals, we will need to double the rate of progress made during the Millennium Development Goal era. We believe that the fastest way to interrupt the transfer of risk from mother to baby is to address underlying biological vulnerabilities, such as malnutrition and pre-term birth.

Our Growth and Resilience framework shifts focus away from development of tools for single disease conditions, and towards innovative tools that can alter the trajectory of biological vulnerability potential game-changers for maternal, newborn and child survival. To develop these tools, our focus is on innovating in areas that reduce adverse birth outcomes, improve growth, optimize neurodevelopment, and enhance resilience to infection.

Sindura Ganapathi

Bill & Melinda Gates Foundation | Discovery & Translational Sciences | Deputy Director | United States of America

SPEAKERS

Rajiv Bahl

World Health Organization (WHO) | MCA Department | Maternal, Newborn, Child and Adolescent Health Research and Development Team | Coordinator | Switzerland

Stefan Dräger

Drägerwerk Verwaltungs AG | Chairman of the Executive Board | Germany

Katharina Lichtner

Family Larsson-Rosenquist Foundation | Managing Director | Switzerland

Rebecca Richards-Kortum

William Marsh Rice University | Rice 360° Institute for Global Health | Director | United States of America



Rajiv Bahl



Katharina Lichtner



Stefan Dräger



Rebecca Richards-Kortum



Sindura Ganapathi

WS 14

SAAL 2 | AMERICA 9:00-10:30





ONE HEALTH

A Continuous Challenge for Science and Healthcare

HOSTS

Leibniz Association

German Federal Ministry of Education and Research (BMBF)

Zoonotic virus infections may lead to major economic losses and disease burden in animals and man. Herein, particularly emerging viruses, such as avian influenza, MERS-CoV and ZIKV challenge current surveillance and health care systems. Moreover, evolving avian influenza viruses pose a major pandemic threat. This highlights the urgent need for network collaborations involving scientists, clinicians and public health

experts working at the animal-human interface. As a major global health challenge, pandemic preparedness plans need to consider the holistic One Health concept.

This session will focus on the current challenges posed by emerging viruses to animal and human health as well as discuss potential counterstrategies to reduce disease burden.

Heribert Hofer

Leibniz Institute for Zoo and Wildlife Research | Director | Germany

SPEAKERS

Gülsah Gabriel

Heinrich Pette Institute | Viral Zoonoses - One Health | Head | Germany

Barbara Rath

Vienna Vaccine Safety Initiative (ViVI) | Co-Founder and Chair | Germany

Yuelong Shu

National Institute for Viral Disease Control and Prevention of China CDC | Deputy Director | China

Marc Sprenger

World Health Organization (WHO) | Antimicrobial Resistance Secretariat | Director | Switzerland



Gülsah Gabriel

Yuelong Shu



Heribert Hofer



Marc Sprenger



Barbara Rath

WS 15

SAAL 4 | AFRICA 9:00-10:30



EBERHARD KARLS UNIVERSITÄT TÜBINGEN







WORKSHOP

NEGLECTED TROPICAL DISEASES AND THEIR CO-MORBIDITIES

How They Affect Healthcare Systems

HOSTS

Association of Research-based Pharmaceutical Companies (vfa)

Eberhard-Karls-University Tübingen

German Network against Neglected Tropical Diseases (DNTDs)

German Society for Tropical Medicine and International Health (DTG)

Universitätsklinikum Tübingen

More than 1.4 billion people around the world are infected with at least one NTD. The systemic impact of these diseases is considerable, not just because of the sheer number of those affected. but also because people suffering from NTDs have a higher risk of acquiring other diseases, such as HIV and AIDS, tuberculosis, cancer, diabetes and often develop various forms of physical disabilities, often requiring medical assistance. Women and girls suffering from NTDs, such as anaemia caused by hookworm infection or schistosomiasis have a higher risk of potentially lethal complications during childbirth. People suffering from NTDs also disproportionally suffer from

stigma associated with disabilities and often develop constraints in their mental health status.

This session aims at highlighting the consequences and opportunities of integrating NTDs into the health system strengthening approach that the German government has recently introduced into the global health agenda. Programs to combat NTDs have a beneficial effect on health systems, because they substantially reduce the burden of diseases the systems have to cope with. They can also strengthen other preventive programs, such as mother-and-child programs and initiatives to fight hunger and poverty.

Carsten Köhler

University Hospital Tübingen | Institute of Tropical Medicine | Center of Competence | Director | Germany

SPEAKERS

Christoph Benn

The Global Fund to Fight AIDS, Tuberculosis and Malaria | External Relations | Director | Switzerland Bridge to HIV/Aids

Katey Einterz Owen

Bill & Melinda Gates Foundation |
Department of Neglected Tropical
Diseases | Director |
United States of America
Bridge to Co-Morbidities in General

Dirk Engels

Health Consultant | Neglected Tropical Diseases | Switzerland Impulse Statement Co-Morbidities

Narcis Kabatereine

Imperial College London | Faculty of Medicine, School of Public Health | MER Advisor | United Kingdom Persistent High Schistosomiasis Morbidity in Uganda Despite 13 Years of Annual Mass Drug Administration

Francisca Mutapi

University of Edinburgh | Parasite Immuno-Epidemiology Group | Head | United Kingdom

From Pediatric Schistosomiasis to NCDs in Adulthood



Christoph Benn

Narcis Kabatereine



Katey Einterz Owen

Carsten Köhler



Dirk Engels

Francisca Mutapi

WS 16

SAAL 5 | OCEANIA 9:00-10:30









BETTER LEADERSHIP: IMPROVED HEALTH

Young Physician Leaders: "The Leadership We Want"

HOSTS

ESMT European School of Management and Technology GmbH InterAcademy Partnership (IAP)

Successful institutions need good leaders. And whether they are in high income countries or poorer countries, institutions providing healthcare, educating future physicians or promoting the public's health are no different. Yet decision-makers in such institutions are often appointed from among people trained in medicine, with little formal training in leadership to prepare them for these roles.

The InterAcademy Partnership (IAP) Young Physician Leaders (YPL) program aims to bridge this gap. Launched in 2011, to date some 155 young physicians from some 45 countries have participated in six international and one regional editions of this personalized leadership training program (a dedicated IAP for Health YPL Directory is available here: www.iamponline.org/iamp-young-physician-leadersdirectory).

Jo Ivey Boufford

New York Academy of Medicine | President | United States of America

Nora Ilona Grasselli

ESMT European School of Management and Technology GmbH | Program Director | Germany

Peter McGrath

InterAcademy Partnership (IAP) | Program Officer | Italy



Jo Ivey Boufford

Peter McGrath



Nora Ilona Grasselli

SPEAKERS

Selected from among the 2018 Cohort of Young Physician Leaders

KEYNOTE

KEY 02

SAAL 1 RUDOLF VIRCHOW 11:00-12:30

VACCINE PRODUCTION AND DELIVERY SYSTEMS

BILL & MELINDA GATES foundation

> Heidelberg Institute of Global Health



HOSTS

Bill & Melinda Gates Foundation

Heidelberg Institute of Global Health

PATH

When it comes to fighting infectious diseases, vaccines offer top economic and social value, and they also represent the best means for controlling and eliminating dangerous communicable pathogens. Intensified global efforts to step up vaccine research and development are

therefore a must, especially for neglected tropical diseases. A central challenge is that in some developed countries, where popular perceptions no longer view infection or epidemics as a serious risk, mindsets will need to change.

Till Bärnighausen

Heidelberg Institute of Global Health | Director | Germany

SPEAKERS

Seth Berkley

Gavi, The Vaccine Alliance | CEO | Switzerland

Steve Davis

PATH | President and CEO | United States of America

Frederik Kristen Ole Kristensen

Coalition for Epidemic Preparedness Innovations (CEPI) | Deputy CEO | Norway

Gayle E. Smith

ONE | President and CEO | United States of America

Lynda Maria Stuart

Bill & Melinda Gates Foundation | Deputy Director United States of America



Bärnighausen



Frederik Kristen Ole Kristensen



Seth Berkley



Gavle E. Smith



Steve Davis



Lvnda Maria Stuart

PANEL DISCUSSION

PD 05

SAAL 6 | EUROPE 11:00-12:30

VALUE BASED HEALTH CARE

The Panacea for our Healthcare Woes



HOSTS

M8 Alliance:

National University of Singapore (NUS)



What is the issue?

Global healthcare spending has reached an estimated USD 7-8 trillion, a third of which is reported to be "wasted". The misalignments of incentives, interests, strategies and behaviors of parties engaged in healthcare delivery (i.e. policy makers, regulators, private sector, R&D, providers, suppliers and individuals) are at the core of this inefficiency. Healthcare -in countries where people can benefit from it- is therefore imprecise and inequitable. The misalignments amongst healthcare stakeholders have led to dead ends at the financial (unsustainable costs), human (outcomes far from delivering the expected quality of care) and systemic levels (high degrees of variability between delivery systems).

How can this issue be addressed?

What is known as value-based health care (VBHC) has aimed to redefine how care is organized, measured, and reimbursed. Today, the concept is pushed further with the massive spread of technology, systems and devices allowing for almost real-time evidence-informed strategies and decision-making in healthcare that, in principle, could allow tailoring of care to the needs and differences of each individual and ecosystem.

Diarmuid Murphy

National University Hospital (NUH) | Chief Value Officer | Singapore

SPEAKERS

John Amuasi

Kumasi Center for Collaborative Research in tropical Medicine KNUST -Research Group Leader (AG AMUASI)

Ricardo Augustus Guerreiro Baptista Leite

Catholic University of Portugal | Institute of Health Sciences | Head of Public Health | Portugal Parliament of Portuguese Republic | Health Committee | Portugal

Jens Grueger

Roche Pharmaceuticals | Vice President, Head of Global Pricing & Market Access | Switzerland

Richard Jansen

Medtronic GmbH | Integrated Health Solutions Europe & Russia | Senior Director | Germany

Gregory Katz

University Paris Descartes | Innovation Management & Healthcare Performance | Chair | France

Nathalie Moll

European Federation of Pharmaceutical Industries and Associations (EFPIA) | Director General | Belgium



John Amuasi



Gregory Katz



Ricardo Augustus Guerreiro Baptista Leite



Nathalie Moll



Jens Grueger



Diarmuid Murphy



Richard Jansen

WS 15a

SAAL 4 | AFRICA 11:00 - 12:30

HZI HELMHOLTZ
Centre for Infection Research



DIGITAL INTEGRATION OF SURVEILLANCE AND OUTBREAK RESPONSE MANAGEMENT

HOST

Helmholtz Centre for Infection Research (HZI)

The recent outbreaks of Ebola Virus Disease in Central and West Africa are only the most prominent indications of tragic failures in outbreak detection. They also exemplify the tremendous challenge of managing the response to such outbreaks, given dramatically under resourced health care systems, societal instability and deficient information and transportation infrastructure in many parts of the world.

At the same time, modern digital information technology is becoming increasingly available even in less developed areas and may offer an opportunity to intelligently overcome aforementioned challenges.

In the recent years a large number of initiatives have come up with mobile electronic health tools (mHealth) to address continuous notifiable disease surveillance. Some tools address the response management during an outbreak such as follow-up of contact persons. Only a very small number of tools seem to comprehensively combine continuous surveillance and outbreak response, as proposed by the concept of Integrated Disease Surveillance and Response (IDSR).

With the objective to stimulate technical progress and interoperability in this field, this workshop aims to bring together among the most comprehensive initiatives of digital surveillance and outbreak response management for exchange of concepts and experiences.

Denise Cardo

Centers for Disease Control and Prevention (CDC) Health Quality Promotion | Division Director | United States of America

Jay Varma

Africa Centers for Disease Control | Senior Advisor | Ethiopia

SPEAKERS

Evelyn Castle

eHealth Africa | Executive Director & Co-Founder | United States of America

Chikwe Ihekweazu

Nigeria Centre for Disease Control (NCDC) Chief Executive Officer/ National Coordinator | Nigeria

George C. Kauki

Ministry of Health, Community Development, Gender, Elderly and Children | National IDSR Coordinator | Tanzania

Gérard Krause

Helmholtz Centre for Infection Research (HZI) | Department for Epidemiology | Head | Germany

Sonia Panzani

Terre des Hommes Foundation | Health Programme Coordinator Africa | Switzerland

Boris Pavlin

World Health Organization (WHO) | Health Operations Monitoring & Data Collection Switzerland

David Randolph Wilson

Management Sciences for Health (MSH) | Rwanda Health System Strengthening Activity eam Leader: Knowledge Management, Data Use and Research | Rwanda



Denise Cardo





Boris Pavlin



Fvelvn Castle



Gérard Krause



David Randolph Wilson



Chikwe Ihekweazu



Sonia Panzani



Varma

WS 16a

SAAL 5 | OCEANIA 11:00 - 12:30

DISEASE X

Will we be able to find it in time and respond appropriately?



HOSTS

German Institute for Defence and Strategic Studies (GIDS)

Global Health Security Alliance



The WHO recently released its updated list of diseases of public health concern. A new addition to that list is "Disease X" which represents "the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease". In January 2018, the World Bank released it's "Operational framework for strengthening human, animal and environmental public health systems at their interface" report. Recognizing that the majority of emerging infectious diseases have originated in

animals, they recommend that it is time to start "targeting disease threats upstream prevention at the source, or via early detection and response) to help reduce the frequency and impact of emergencies the system has to react to".

Now that the need to detect public health threats in animal populations prior to spill over into humans has been recognized, the question is, how will this be accomplished?

Tracey McNamara

Western University of Health Sciences | College of Veterinary Medicine | Professor of Pathology | United States of America

SPEAKERS

Mukesh Chawla

World Bank | Advisor | United States of America Have GHSA investments Gone to the Veterinary Sector?

Ruxandra Draghia

MSD (Merck Sharp & Dohme) | Global Vaccines | Vice President of Public Health and Scientific Affairs | United States of America

Preparing for Disease X - Lessons Learnt from Recent Epidemic Outbreaks

Elizabeth Mumford

World Health Organization (WHO) Department of Country Health Emergency Preparedness and IHR | One Health Country Operations Team Switzerland

Building Multisectoral, One Health Capacity under the International **Health Regulations**

Elmar Nimmesgern

Federal Ministry of Education and Research (BMBF) | Head of Global AMR R&D Hub | Germany A One Health Approach to Tackle the Spread of AMR in Humans, Animals

Sophie von Dobschuetz

and the Environment

Food and Agriculture Organization | Global Surveillance Coordinator | Italy **FAO's Surveillance Evaluation Tool** (SET): Outcomes of 13 Missions on Assessment of Animal/Zoonotic **Disease Surveillance Systems**

James Wilson

Lessons Learned?

University of Nevada, Reno | Nevada Medical Intelligence Center | Director | United States of America Medical Intelligence Failures -

Lisa Yon

University of Nottingham | School of Veterinary Medicine and Science | Lecturer in Zoo and Wildlife Medicine United Kingdom

The Status of Wildlife Disease Surveillance in the EU



Mukesh Chawla

Flmar Nimmesgern



Ruxandra Draghia



Sophie von Dobschuetz



Tracev McNamara

James Wilson



Elizabeth Mumford



Lisa Yon

KEYNOTE

KEY 03

SAAL 1 RUDOLF VIRCHOW 14:00-16:00

ANTIMICROBIAL RESISTANCE







HOSTS

German Federal Ministry of Education and Research (BMBF)

German Center for Infection Research e.V. (DZIF)

Robert Koch Institute

Antimicrobial Resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections are becoming harder, and sometimes impossible, to treat as antibiotics become less effective. This crisis is global, reflect-

ing the worldwide overuse of these drugs and the lack of development of new antibiotic agents by pharmaceutical companies to address the challenge. Coordinated efforts to implement new policies, renew research efforts, and pursue steps to manage the crisis have been created over the recent period, but major gaps still remain.

Lothar H. Wieler

Robert Koch Institute | President | Germany

SPEAKERS

Georg Schütte

Federal Ministry of Education and Research (BMBF) | State Secretary | Germany

Thomas B. Cueni

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland

Jeremy Farrar

Wellcome Trust | Director | United Kingdom

Jayasree Iyer

Access to Medicine Foundation | Executive Director | Netherlands

Rolf Müller

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) | Managing Director and Head of Department of Microbial Natural Products (MINS) | Germany



Thomas B. Cueni

Rolf Müller



Jeremy Farrar

Georg Schütte



Jayasree Iyer

Lothar H. Wieler

PANEL DISCUSSION

PD 06

SAAL 6 | EUROPE 14:00 - 16:00

BIG DATA ANALYTICS IN BIOMEDICAL RESEARCH AND HEALTHCARE



CHARITÉ UNIVERSITĂTSMEDIZIN BERLIN



HOSTS

Berlin Institute of Health (BIH)

M8 Alliance:

Charité - Universitätsmedizin Berlin

Data is now a cornerstone of the healthcare industry. It documents everything from blood pressure readings and surgical records to insurance claims, immunization histories, patient demographics and receipts of payment. But even though Big Data may bridge the gap between healthcare delivery and population health and improve many health outcomes through enhanced methods of research, the detailed collection of personal information poses ethical, regulatory and technical challenges. In addition, much of the promise of Big Data in health care is still awaiting confirmation through evidence from large trials of high quality.

This session will explore the opportunities but also the challenges for Big Data to assist governments and health care providers in delivering maximum benefit to society. Big Data will drive fact-based decisions by policy makers and shape how health systems address societal and global challenges in both developed and developing economies. The increased scope, detail and availability of patient and population data will also influence the broader debate around data governance and the associated ethical issues. Our panelists will discuss technological, commercial, statistical, ethical, practical, as well as policy issues which we encounter when moving from small to Big Data to help clinical practice management, surveillance, health system management, and research and innovation.

Ulrich Dirnagl

Berlin Institute of Health (BIH) | QUEST Center for Transforming Biomedical Research | Founding Director | Germany

SPEAKERS

Roland Eils

Berlin Institute of Health (BIH) | Center for Digital Health | Founding Director | Germany

Bernd Montag

Siemens Healthineers AG | CEO | Germany

Nicola Perrin

Wellcome Trust | Data for Science and Health Priority | Head | United Kingdom

Barbara Prainsack

University Vienna | Comparative Policy Analysis | Professor | Austria

Stephen Senn

Luxembourg Institute of Health | Statistics | Professor | Luxembourg



Ulrich Dirnagl

Nicola Perrin



Roland Eils

Barbara Prainsack



Bernd Montag

Stephen Senn

WS 15b

SAAL 4 | AFRIKA 14:00-16:00

THE BEAUTY OF IMPACT: DISRUPTIVE INNOVATIONS FOR FOOD-RELATED HEALTH CHALLENGES

Creating Desirable Futures



HOST

Bayer Foundations

Humanity is facing grand challenges and pressing needs in health and food. In an ever advancing world of tech innovations an increasing number of people is left behind in poverty, starvation and bad health. Hunger, food and health crisis are global threats with capability to out-balance the world as we know it. This session is about impact pioneers who are creating new answers for food-related health challenges. Their innovations have the power to bring prosperity and opportunity to the raising billions in need.

The session showcases health and food activists from all continents demonstrating how grand challenges can be turned into big opportunities. This is a tribute to those courageous men and women who dare to brave the unknown for the purpose of shaping the future of humanity. They are icons of progress – let them inspire you to become a change maker yourself.

CHAIR

Thimo V. Schmitt-Lord

Bayer Foundations | CEO | Germany

Introduction: Start a Business - Save the World

SPEAKERS

Jeannette Countess Beissel von Gymnich

Jeannette Gräfin Beissel von Gymnich-Foundation | Founder | Germany

Changemakers Inspire Us All to Go Further

Social Impact Startups

> AI SCOPE

Al Backed Diagnosis in Low Income Regions **Eduardo Peire**

Mechanical Engineer

> CLEARKARMA

Blockchain Backed Solution for Food Safety

Sylvie Chin

ClearKarma | Founder and CEO

> COOLAR

Electricity Free Food and Drug Cooling Systems

Christoph Göller

Coolar | Co-Founder

> LEONYTE

Real-Time, Reliable Bacteria Detection System for Food Safety and Health

Facundo Gomez Vera

Leonyte Biosystems | CEO

Marc Buckley

ANJA GmbH & Co. KG | Founder and CEO | UN SDG Advocate, Food Reformist, Sustainable Farming Futurist | Germany

How the Sustainability Goals Can Love us Back

> SOS-VILLAGE HOHENROTH

Model Farm for Mentally Disabled People

Alexander Seith

SOS Model Farm Hohenroth | Divisional Director

> THRIVING GREEN

Future Farming with Superfood Spirulina

Alexander Zacharuk

Thriving Green | Founder

> WORLD FOOD PROGRAMME

Tech innovations to end hunger Bettina Luescher

World Food Programme | Chief Spokesperson, Berlin







Jeannette Countess Bettina Beissel von Gymnich Luescher

Facundo Gomez Vera



Eduardo

Peire



Alexander Zacharuk



Svlvie Chin

Buckley



Thimo V. Schmitt-Lord



Christoph Göller



Alexander Seith

WS 16b

SAAL 5 | EUROPE 14:00 - 16:00







HEALTHCARE SYSTEMS IN LATIN AMERICA

Achieving Health for All

HOSTS

Cluster Médico Jalisco AC

German Healthcare Partnership (GHP)

Joint United Nations Programme on HIV/AIDS (UNAIDS)

In this workshop a broad spectrum of private sector, community, scientific and political representatives will draw on their experiences and discuss progress and obstacles in achieving equitable healthcare in Latin America. The panelmembers will examine this on the basis

of different healthcare system models in Latin America and will also focus on marginalized populations, who do not have access to healthcare. In this context, specific attention will be given to the role of communities in healthcare provision to ensure access to health for all.

Roland Göhde

German Healthcare Partnership (GHP) | Chairman of the Board | Germany

Georgina Garcia Martinez

Cluster Médico Jalisco AC | President | Mexico

Michel Sidibé

Joint United Nations Programme on HIV/AIDS (UNAIDS) | Executive Director | Switzerland



Verónica Espinosa

Georgina Garcia Martinez

SPEAKERS

Verónica Espinosa

Ministry of Health | Minister | Ecuador

Carlos Jimenez

Mexican Association of Innovative Medical Device Industries (AMID) | President | Mexico

Georg Kippels

German Bundestag | Member of the Parliament & Deputy Chairman of the German-Mexican Parliamentary Friendship Group | Germany

Suzanna Tkalec

Caritas Internationalis | Humanitarian Director



Roland Göhde



Michel Sidibé



Carlos Jimenez

Suzanna Tkalec



Georg Kippels

PANEL DISCUSSION

PD 07

SAAL 6 | EUROPE 16:30-18:00



Towards a Safer World



HOSTS

Federal Ministry for Economic Cooperation and Development (BMZ)

KfW Group



To prevent a disease outbreak from turning into an epidemic or even a pandemic which may cause significant social and economic damage, preparedness and an early response is essential. This requires sufficient and timely funding as well as structures which are in a position to respond fast and adaquately. Pandemic insurance promises to avoid lengthy humanitarian appeals and make financing available when needed to contain deadly outbreaks. How does pandemic insurance fit into the global financing architecture

for pandemic preparedness? How does pandemic insurance work in practice? Is pandemic insurance all it takes to contain major disease outbreaks? And what role does it play from the (re-)insurance industry's point of view? Would countries be ready to pay insurance premiums to be covered in case of emergency? These questions will be discussed in this session that brings together representatives of WHO, the World Bank, the African Risk Capacity, civil society, reinsurance industry as well as the partner countries.

PROGRAM, MON 15

CHAIR

Peter Piot

London School of Hygiene & Tropical Medicine (LSHTM) | Director & Professor of Global Health | United Kingdom Member of the German National Academy of Sciences Leopoldina

SPEAKERS

Robert Kwame de Graft Agyarko

African Risk Capacity | Outbreaks and Epidemics | Lead Advisor | South Africa

Timothy Grant Evans

World Bank | Health, Nutrition & Population | Senior Director | United States of America

Marjeta Jager

European Commission | International Cooperation and Development | Deputy Director-General | Belgium

Stanley Okolo

West African Health Organization (WAHO) | Director General | Burkina Faso

Peter Salama

World Health Organization (WHO) | Deputy Director-General of Emergency Preparedness and Response | Switzerland

Paul Stoffels

Johnson & Johnson | Vice Chair of the Executive Committee and Chief Scientific Officer | United States of America



Robert Kwame de Graft Agyarko

Peter Piot



Timothy Grant Evans

Peter Salama



Marjeta Jager

Paul Stoffels



Stanley Okolo

WS 17

SAAL 10 | ASIA 16:30-18:00

SEXUAL VIOLENCE

The Impact of Globalization



HOSTS

M8 Alliance

Charité - Universitätsmedizin Berlin



Prevalence rates derived from epidemiological studies confirm that sexual violence against women and children represents a serious global health problem. Research in victims demonstrates marked long-term effects which contribute to health problems.

Against this background the session will adress this huge burden in a changing society with new technologies enhancing the risk of sexual traumatization on the one hand and offering new perspectives in combating this on the other.

It will be discussed that sexual violence is promoted by cultural factors oppressing women and enhancing misogynic attitudes. Furthermore, it will highlight the new technologies (internet) for inappropriately contacting minors (e.g. grooming behavior) and distributing child abuse images, as well as promoting cultural conflicts and anti-women attitudes via the worldwide availability of pornographic materials denoting the umbrella of cognitive distortions concerning sexuality.

The workshop will scrutinize the knowledge to devise strategies for using the internet and new technologies themselves for the prevention of sexual violence against children and women.

Klaus Michael Beier

Charité - Universitätsmedizin Berlin | Institute of Sexual Sciences and Sexual Medicine | Director | Germany

SPEAKERS

Avni Amin

World Health Organization | Department of Reproductive Health and Research | Technical Officer, Violence Against Women | Switzerland

Sexual Violence and Global Health

Janavi Doshi

The HEAL Foundation |
Primary Prevention of Sexual Violence |
Program Director | India
Chances for Reducing Sexual
Traumatization via New Technologie

Ateret Gewirtz-Meydan

University of New Hampshire | Crimes against Children Research Center | Postdoctoral Fellow | United States of America Survivors of Child Sexual

Julia von Weiler

Exploitation Imagery

Innocence in Danger e.V. | Director | Germany

The Impact of New Technologies: Risks for Sexual Traumatization



Avni Amin

Ateret Gewirtz-Meydan



Klaus Michael Beier



Julia von Weiler



Janavi Doshi

WS 18

SAAL 2 | AMERICA 16:30-18:00

COORDINATION OF GLOBAL HEALTH SUPPORT

The Advantages of a Coordinated Response to Global Health Challenges



HOST

German Federal Ministry of Health (BMG)

In order to achieve SDG3 and other health-related targets of the 2030 Agenda for Sustainable Development as well as to address Global Health challenges, coordination at all levels – national, regional and international – is imperative. Especially, the intersectoral cooperation and coordination across stakeholder groups is important. At the same time, this cooperation and coordination remains a key challenge.

The objective of this session is to present and discuss different approaches to coordination. The workshop will bring together key stakeholders who share their experiences, lessons learnt and best practices on different coordination measures and mechanisms. Representatives from different countries and civil society will exchange on principles and priority areas of their Global Health engagement, ways of ensuring a coordinated approach across sectors and stakeholder groups.

Ilona Kickbusch

The Graduate Institute of International and Development Studies | Global Health Center | Director | Switzerland

SPEAKERS

Maria Nazareth Farani Azevêdo

Permanent Mission of Brazil to the United Nations in Geneva | Permanent Representative | Brazil Coordination between BRICS Countries and the Importance of Health Diplomacy

Björn Kümmel

Federal Ministry of Health (BMG) | Division of Global Health | Deputy Head | Germany

Global Health Coordination at the National Level - Experience and Lessons Learnt from Germany

Colin Mciff

U.S. Department of Health and Human Services | Office of Global Affairs | Deputy Director | United States of America A Coordinated Approach to Global Health - Government Coordination between Capital and Permanent Missions

Maike Röttger

Plan International Germany e.V. | CEO | Germany

Coordination among Civil Society
Organizations – Examples and Lessons
Learnt

Päivi Sillanaukee

Ministry of Social Affairs and Health | Permanent Secretary | Finland Coordination among Nordics on Global Health Issues, including within WHO



Maria Nazareth Farani Azevêdo

Colin Mciff



llona Kickbusch

Maike Röttger



Björn Kümmel

Päivi Sillanaukee

WS 19

SAAL 4 | AFRICA 16:30 - 18:00





HOSPITAL PARTNERSHIPS FOR IMPROVED SERVICE DELIVERY

Strengthening Competencies of Medical Personnel

HOSTS

Federal Ministry for Economic Cooperation and Development (BMZ)

The Else Kröner-Fresenius Stiftung

The Initiative Hospital Partnerships -Partners strengthen Health promotes partnerships between health organizations in Germany and medical institutions in low- and middle-income countries in order to improve healthcare outcomes by enhancing the quality, education and delivery of healthcare worldwide. Professionals such as physicians, nurses, public health specialists, midwives, lab technicians and hospital managers meet on equal terms and share expertise, experiences and ideas to improve healthcare in selected thematic areas. The initiative is funded by the Federal Ministry for Economic Cooperation and Development (BMZ) in cooperation with the Else

Kröner-Fresenius-Foundation (EKFS) and aims to support the 2030 Agenda with a particular focus on SDG 3 and SDG 17.

The purpose of this session is to explore effects, outcomes and success factors of these collaborations and to identify key lessons learned from current partnerships in terms of opportunities, challenges, barriers and enablers. Stakeholders and healthcare leaders from high-income and low-income countries reflect on their partnership activities, share potentials, expectations and benefits with the audience but also discuss issues concerning sustainability, contributions to the global health agenda and quality of care.

Oliver Haas

German Society for International Cooperation (GIZ) Health, Education, and Social Affairs | Head of the Global Division | Germany

SPEAKERS

Michael Madeja

Else-Kröner-Fresenius-Stiftung CEO | Germany

Introduction & Welcome

Shamsuzzoha Babar Syed

World Health Organization (WHO) | Coordinator | Switzerland

Quality of Care in Twinning Projects

Daniel Burssa

Federal Ministry of Health | Chief of Staff | Ethiopia

Health System Strengthening

Yadeta Dessie

Haramaya University | College of Health and Medical Sciences | Chief Executive Director | Ethiopia

Hospital Partnership Mother and Child Health

Annegret Kiefer

Eichsfeld Hospital | Obstretics and Gynecology | Chief Physician | Germany **Hospital Partnership Mother** and Child Health

Gisela Schneider

Deutsches Institut für ärztliche Mission | Director | Germany

Hospital Partnership Patient Safety, AMR

Augustin Sendegeya

University Teaching Hospital of Butare (CHUB) | Director | Rwanda

Improved Patient Safety

Hans-Peter Baur

Federal Ministry for Economic Cooperation and Development (BMZ) | Principle | Germany **Closing Statement**





Shamsuzzoha Babar Syed

Yadeta Dessie

Michael Madeja



Hans-Peter Baur



Haas

Gisela Schneider



Daniel Burssa



Annegret Kiefer



Augustin Sendegeya

WS 20

SAAL 5 | OCEANIA 16:30 - 18:00







ANTIBIOTIC RESEARCH & DEVELOPMENT

Ensuring Effective and Affordable Antibiotic Treatments for The Future of Humankind

HOSTS

German Federal Ministry of Education and Research (BMBF)

German Center for Infection Research e.V. (DZIF)

Helmholtz Centre for Infection Research (HZI)

Modern medicine is not conceivable without effective antibiotic treatment. Curing infectious diseases would hardly be possible without antimicrobial agents. However, overuse and misuse of antibiotics in hospitals and agriculture have substantially increased the spread of antimicrobial resistance (AMR). Alarmingly, the dramatic worldwide rise of multi- and pan-resistant pathogenic strains cannot be contained by the low success rates of current drug development. In fact, only a small fraction of the antibiotics approved over the last 40 years represent novel compound classes. If there is no significant future progress, the World Health Organization considers a "post antibiotic era" a realistic future scenario in which, for example, pneumonia and wound infections once again could become acute life-threatening diseases.

This workshop addresses key problems in modern antibiotic research and development from both academic and industrial perspectives and shall raise public awareness that novel antibiotics are indispensable to sustain our future quality of life. At the same time, pointing out the challenges and unavoidable costs of antibiotic drug development may help to change the political attitude towards stronger investments into sustainable scientific programs for drug development, ideally in partnership with global health organizations and industry. Innovative approaches to strengthen the discovery of novel antibiotics and to bridge the translational gap towards the clinical optimization of new therapeutics will be presented.

CHAIRS

Achim Hörauf

Bonn University Medical Center | Institute of Medical Microbiology, Immunology and Parasitology | Director | Germany

Rolf Müller

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) | Director | Germany



Heike Brötz-Oesterhelt

Heinz Moser

SPEAKERS

Heike Brötz-Oesterhelt

Eberhard-Karls-University Tübingen |
Department of Microbial Bioactive
Compounds | Head | Germany
Antibiotic Research & Development
in the German Center for Infection
Research e.V. (DZIF)

Matthew Cooper

The University of Queensland | Institute for Molecular Bioscience | IMB Centre for Superbug Solutions | Director | Australia

Antibiotic Research & Development from the Academic Perspective

Heinz Moser

Novartis Institutes for BioMedical Research (NIBR) | Infectious Diseases Chemistry | Executive Director | United States of America Antibiotic Research & Development

Laura Piddock

Global Antibiotic Research &
Development Partnership (GARDP) |
Scientific Affairs | Head | Switzerland
Antibiotic Research & Development
from the Global Health Perspective

from the Industrial Perspective



Matthew Cooper




Rolf Müller



Achim Hörauf



Laura Piddock



PROGRAM

TUESDAY, OCTOBER 16

PANEL DISCUSSION

PD 08

SAAL 6 | EUROPE 9:00-10:30

HEALTH SYSTEMS STRENGTHENING



HOSTS

M8 Alliance:

Johns Hopkins Bloomberg School of Public Health



The world has never possessed such a sophisticated arsenal of interventions and technologies for curing disease and prolonging life. Yet the gaps in health outcomes continue to widen. For much of the ill health, disease, premature death, and suffering we see on such a large scale, effective and affordable interventions are available for prevention and treatment.

The power of existing interventions is not matched by the capacity of health systems to deliver them to those in greatest need, in a comprehensive way, and on an adequate scale. Smart investments and efficient system development must be the center piece of domestic policies and financing.

PROGRAM, TUE 16

CHAIR

Adnan A. Hyder

Johns Hopkins Bloomberg School of Public Health | Health Systems Program | Professor and Director | United States of America

The George Washington University | Milken Institute School of Public Health | Senior Associate Dean for Research and Professor of Global Health

SPEAKERS

Diane Gashumba

Ministry of Health | Minister of Health | Rwanda

Steven Hildemann

Merck KGaA | Global Medical Affairs and Global Drug Safety | Global Chief Medical Officer | Germany

Rüdiger Krech

World Health Organization (WHO) | Universal Health Coverage & Health Systems | Director | Switzerland

Sandhya Venkateswaran

Bill & Melinda Gates Foundation | Policy & Advocacy | Senior Program Officer | United States of America



Diane Gashumba

Rüdiger Krech



Steven Hildemann

Sandhya Venkateswaran



Adnan A. Hyder

WS 21

9:00-10:30

DIGITAL HEALTH IN DEVELOPING COUNTRIES

Opportunities & Challenges Ahead



HOSTS

Federal Ministry for Economic Cooperation and Development (BMZ)

German Society for International Cooperation (GIZ)



The rapid adoption of computers, mobile phones and the internet over the last two decades have transformed the way lives are lived globally. While most cuttingedge innovations in the field of Digitalization are taking place in high-income countries. low and middle-income countries are also undergoing digital transformation albeit to a lesser degree. Going forward, due in part to the continuous decline in the cost of Information and Communication Technology (ICT), the rate of adoption will only keep accelerating allowing for low and middle-income countries to further capitalize on the ICT and Digital revolution.

Across different functions of the health system such as service delivery and resource management, digital tools promise to improve the status quo. This session aims to

- Evaluate the status of digital health development in selected low-middle income countries.
- Analyse successes and determine whether these brought positive changes.
- Explore lessons learnt in the development process.
- Find best practices in stakeholder cooperation to better further the Digital Health agenda.
- Present and adopt the Principles of Donor Alignment for Digital Health

PROGRAM, TUE 16

CHAIR

Kelvin Hui

German Society for International Cooperation (GIZ) | Digital Health and Social Protection | Technical Advisor | Cambodia

SPEAKERS

Hans-Jochen Heinze

University of Magdeburg | Department of Behavioral Neurology | Clinic Director | Germany Tele Medical GmbH | Consultant | Germany

Haitham El-Noush

Norwegian Agency for Development Cooperation | Department for Education and Global Health | Senior Adviser | Norway

Andrew Likaka

Ministry of Health | Quality Management Directorate | Director | Malawi

David Stanton

United States Agency for International Development (USAID) | Bureau Lead for Digital Health | United States of America

Tim Wood

Bill & Melinda Gates Foundation | Global Development | Senior Program Officer | United States of America



Haitham El-Noush

Andrew Likaka



Hans-Jochen Heinze



David Stanton



Kelvin Hui



Tim Wood

WS 22

SAAL 2 | AMERICA 9:00-10:30

CITIES AS DRIVERS OF GLOBAL HEALTH







HOSTS

InterAcademy Partnership (IAP)

International Society for Urban Health (ISUH)

World Federation of Academic Institutions for Global Health (WFAIGH)

Cities can be the critical drivers in achieving global health. Over half the world's population already live in urban environments and this number is projected to grow to 70% in the next 2-3 decades, with fastest growth in LMICs. While cities generate 70% of the world's GDP, they also generate 70% of the world's greenhouse gases and global waste and use over 60% of global energy. Cities can be focal points for improving health within and across national boundaries, but to do so requires a fundamental shift from a dominant global health focus on the prevention and treatment of disease in individuals by strengthening health care systems to increase the emphasis on addressing broader determinants of health. Strategies to improve urban

health must recognize that the health of people living in cities is affected by decisions made in all sectors: built and natural environment, economic development, education, and transport and through inclusive models of governance that promote public engagement. This is a major paradigm shift in international development strategy for health reflected in the first ever urban SDG and Habitat's New Urban Agenda.

This session will set the context for the focus on broader determinants of health and the characteristics of cities that affect the success of health initiatives. Speakers will then present examples of urban health initiatives in the public and private sectors followed by discussion.

PROGRAM, TUE 16

CHAIRS

Jo Ivey Boufford

New York Academy of Medicine | President | United States of America

John Finnegan

World Federation of Academic Institutions for Global Health (WFAIGH) |
President | United States of America
University of Minnesota | School of
Public Health | Dean and Professor |
United States of America



Ann Aerts

Mark Nieuwenhuijsen



Jo Ivey Boufford





John Finnegan

SPEAKERS

Ann Aerts

Novartis Foundation | Head | Switzerland
Better Hearts Better Cities:
A Multisector Initiative Addressing
Hypertension in Low-Income Urban
Communities

Mark Nieuwenhuijsen

ISGIobal Barcelona Institute for Global Health | Urban Planning, Environment and Health Initiative | Director | Spain Urban and Transport Planning: Impacts on Environment and Health

Nelson Sewankambo

Makerere University Medical School |
Former Dean | Uganda
Uganda national Academy of Sciences |
President | Uganda
Urbanization in East Africa and

the Role of Academies of Science

WS 23

SAAL 4 | AFRICA 9:00-10:30







POPULATION BASED COHORT STUDIES AND HEALTH PREDICTION

Challenges and Perspective, from Bioinformatics to Machine-Learning

HOSTS

M8 Alliance

Charité - Universitätsmedizin Berlin

Max-Delbrück-Centrum für Molekulare Medizin (MDC)

Although life expectancy in most countries has continuously increased over the past decades, the importance of chronic diseases will considerably grow over the next 30 years due to the demographic changes in many countries. Effective strategies for the prevention of chronic diseases require accurate data about the causes of these diseases and about the potential magnitude of decrease in chronic disease occurrence by avoiding major risk factors. Prospective cohorts represent the optimal design for epidemiologic studies on the causes of chronic diseases. Such cohort studies have a long tradition and already provided important information on risk factors for decision making in many areas, such as lifestyle (e.g. smoking), nutrition (e.g. obesity), environmental factors (e.g. air pollution), or medicine (e.g. high blood pressure).

Yet, the etiology of many diseases is still not completely understood, and many risk factors are only incompletely characterized. In addition, the rapid advancement of modern high-throughput laboratory techniques and computational developments hold promise for more precise risk characterization in the field of personalized prevention. Over the past years, many countries have therefore supported the implementation of newer, large-scale cohort studies. The current workshop will present and discuss current opportunities and challenges of large population based cohort studies from different angles, including science and policy. This includes discussion of the experience of longer established cohort studies, as well as of expectations from newer large-scale cohort studies.

CHAIRS

Tobias Pischon

Max Delbrück Center for Molecular Medicine (MDC) | Head of Molecular Epidemiology Research Group | Germany

Yik-Ying Teo

National University of Singapore (NUS) | Saw Swee Hock School of Public Health | Dean | Singapore



Solomon Iyasu

Tobias Pischon

SPEAKERS

Tobias Pischon

Max Delbrück Center for Molecular Medicine (MDC) | Head of Molecular Epidemiology Research Group | Germany

Introduction

Christoph Lippert

Max Delbrück Center for Molecular Medicine (MDC) | Group Leader Statistical Genomics | Germany Hasso Plattner Institute | Faculty of Digital Engineering | Researcher | Germany

Machine Learning

Annette Peters

Helmholtz Zentrum München German Research Center for Environmental Health | Institute of Epidemiology | Director | Germany

NAKO Study

Elio Riboli

Imperial College London | Faculty of Medicine | School of Public Health | Chair in Cancer Epidemiology and Prevention | United Kingdom

Research and Public Health Lessons Learnt from the European Prospective Investigation on Cancer

Yik-Ying Teo

National University of Singapore (NUS) | Saw Swee Hock School of Public Health | Dean | Singapore

Singapore Studies

Solomon Iyasu

MSD (Merck Sharp & Dohme) | Center for Observational and Real-World Evidence (CORE) | Vice President and Head of Pharmacoepidemiology | United States of America



Christoph Lippert

Elio Riboli



Nicola Perrin



Yik-Ying Teo



Annette Peters

DISCUSSANT

Nicola Perrin

Wellcome Trust | Data for Science and Health Priority | Head | United Kingdom

WS 24

SAAL 5 | OCEANIA 9:00 - 10:30







MAKERERE UNIVERSITY



WORKSHOP

DEVELOPING GLOBAL HEALTH IN ACADEMIC INSTITUTIONS AND MEDICAL CENTERS

Learning from Different Approaches and Experiences

HOSTS

Charité - Universitätsmedizin Berlin

M8 Alliance

tasked with ensuring that regional and national healthcare systems function, both now and in the future, by providing education, research and patient care. At the same time, universities are expected to educate autonomous, open and responsible individuals. As the world is becoming ever more globalized, terms like global citizenship, global impact and global health increasingly find their way into the mission statements and internationalization strategies of universities, including

The session analyzes how academic medical centers around the world deal with global health: What are their motivations to become involved? What role do

Makerere University

Tehran University of Medical Sciences (TUMS)

Academic medical centers are primarily academic medicine. However, operationalizing global health in an institution comes with a number of challenges and questions.

universities play in achieving the Sustainable Development Goals? Given that global health is highly interdisciplinary. how can universities harness the diversity of academic discipline and subject cultures for maximizing their impact? How do they organize and institutionalize global health and how do they finance their global health work? What are the barriers? What do future practitioners expect from global health education and training? How can teaching, research and patient care be effectively linked in the context of global health? What role do North-South or South-South partnerships play, and in what way do they need to be designed in order to ensure that both partners benefit? What opportunities are there to team up with non-university partners in global health? And last but not least, are current approaches suitable to reach their aims?

CHAIR

Michael H. Merson

Duke University | Department of Global Affairs | Vice President and Vice Provost | United States of America

SPEAKERS

Karin Geffert

Global Health Project (GandHI) | Project Lead | Germany German Medical Students Association (bvmd) | National Public Health Officer | Germany

Charles Ibingira

Makerere University | University College of Health Sciences | Prinicpal | Uganda

Ali Jafarian

Tehran University of Medical Sciences (TUMS) | Professor | Iran

Axel Radlach Pries

Charité - Universitätsmedizin Berlin | Dean | Germany

Asghar Rastegar

Yale University | Office of Global Health | Director | United States of America

Oliver Razum

Bielefeld University | School of Public Health | Dean & Head of Department of Epidemiology & International Public Health | Germany



Karin Geffert

Axel Radlach Pries



Charles Ibingira



Asghar Rastegar



Ali Jafarian





Michael H. Merson

PANEL DISCUSSION

PD 09

SAAL 6 | EUROPE 11:00-12:30

INNOVATION FOR IMPACT

The Grand Challenges Model

BILL & MELINDA GATES foundation

Grand Challenges

HOSTS

Bill & Melinda Gates Foundation

Grand Challenges

The session will explore the challenges of building vibrant local innovation ecosystems in low-resource settings, and ways that partners from the private and public sectors are tackling those challenges around the world. The session will specifically introduce World Health Summit participants to Grand Challenges and share its approach to helping local innovators secure funding, connect to local and regional innovation networks and catalyze dedicated health and development innovation communities.

Speakers, representing the Grand Challenges global network, will share how Grand Challenges has evolved over the past decade and supports local innovators in their efforts to address local challenges. They will also explore how the Grand Challenges model strengthens the global innovation ecosystem, complements other innovation platforms and is seeking to help address specific, urgent health challenges.

Public sector representatives may also speak to national and regional R&D prioritization processes and the link between these priorities and the Grand Challenges portfolios of work.

CHAIR

Steven Buchsbaum

Bill & Melinda Gates Foundation | Deputy Director | United States of America

SPEAKERS

Steven Buchsbaum

Bill & Melinda Gates Foundation | Deputy Director | United States of America

Raquel Coelho

National Council for Scientific and Technological Development Brazil | Health | Coordinator | Brazil

Thomas Kariuki

Alliance for Accelerating Excellence in Science in Africa (AESA) | Director | Kenya

Shirshendu Mukherjee

Grand Challenges India | Mission Director | India

Karlee Silver

Grand Challenges Canada (GCC) | Prgrams | Co-Chief Executive Officer (Interim) | Canada



Steven Buchsbaum

Shirshendu Mukherjee



Raquel Coelho

Karlee Silver



Thomas Kariuki

WS 25

SAAL 10 | ASIA 11:00-12:30

ACCESS TO ESSENTIAL MEDICINES



HOST

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

The Sustainable Development Goals acknowledge needs to improve the availability of affordable medicines for the world's poor. Several countries have made substantial progress towards increasing access to essential medicines and treatments to fight HIV/AIDS, malaria and tuberculosis, but access to essential medicines in developing countries is not

adequate and new challenges include the access to NCD medicines. Recent progress in a number of countries show that access to essential medicines can be improved through stronger partnership among governments, pharmaceutical companies and civil society, including consumers, working together to ensure universal access to essential medicines.

CHAIR

Greg Perry

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Assistant Diretor General | Switzerland

SPEAKERS

Jayasree lyer

Access to Medicine Foundation Executive Director | Netherlands

Helen McGuire

PATH | Program Leader, Noncommunicable Diseases | United States of America

Frédérique Santerre

Merck Serono SA | Access to Health | Global Head | Switzerland

Subhanu Saxena

Bill & Melinda Gates Foundation | Regional Director Life Science Europe United States of America

Mariângela Simão

World Health Organization (WHO) | Access to Medicines, Vaccines and Pharmaceuticals | Assistant Director General | Switzerland

Gerald Yonga

East Africa NCD Alliance | Chair | Kenya



Jayasree lyer

Subhanu Saxena



McGuire

Mariângela Simão



Perry



Gerald Yonga



Frédérique Santerre

WS 26

SAAL 2 | AMERICA 11:00 - 12:30



CHALLENGES AND BREAKTHROUGHS ON THE ROAD TO UNIVERSAL HEALTH COVERAGE

HOST

Federal Ministry for Economic Cooperation and Development (BMZ)

Background

SDG 3.8 on UHC envisions that by 2030 all people can use the health services they need, of sufficient quality to be effective, and without facing financial hardship. Despite strong international support for UHC, country level implementation remains challenging. Multi-sectoral approaches involving the whole of government and society are key to generate political will for investment in UHC and drive appropriate reforms.

Aims

In light of the joint responsibility for UHC, this session bridges the gap between the global UHC agenda and national implementation. It explores what needs to change (challenges) and what needs to be preserved and strengthened (breakthroughs) on the road to UHC.

Health, social protection, finance and governance experts illustrate interdisciplinary perspectives on what their sectors offer to UHC and vice versa. High-, middle- and low income countries exchange and learn from each other's experience in aligning conflicting interests to strengthen political will and investments for UHC.

CHAIR

Ilona Kickbusch

The Graduate Institute of International and Development Studies | Global Health Center | Director | Switzerland

SPEAKERS

Oladipupo Hameed

Roche Products Ltd. | Gastroenterologist & Former Regional Medical Director | Nigeria

Piya Hanvoravongchai

Chulalongkorn University | Faculty of Medicine | Professor Equity Initiative: Transformative Leaders for Health Equity | Thailand

Andrew Likaka

Ministry of Health | Quality Management Directorate | Director | Malawi

Sabine Schlacke

University of Münster (WWU) Institute of Environmental and Planning Law | Professor | Germany Advisory Council on Global Change Germany

Amirhossein Takian

Tehran University of Medical Sciences | Department of Global Health & Public Policy | Chair and Professor | Iran



Oladipupo Hameed

Andrew Likaka



Sabine Schlacke Hanvoravongchai



Ilona Kickbusch



Amirhossein Takian

WS 27

SAAL 4 | AFRICA 11:00 - 12:30







PROTECTING PUBLIC HEALTH FOLLOWING ENVIRONMENTAL DISASTERS

Disaster Management

HOSTS

M8 Alliance:

Monash University

M8 Alliance:

London School of Hygiene & Tropical Medicine (LSHTM)

Major environmental disasters are occurring with increasing frequency in high, middle and low income countries around the world. They pose a major challenge for authorities including Environment Protection Agencies and Health Departments. A major responsibility for government is the protection of public health and emergency responders. However, decisions about whether to evacuate populations at risk typically have to be made urgently without good data or

complete knowledge of likely health effects. This session will present some case studies of air pollution, chemical and radiation hazards, and long term followup after a terrorist attack or hurricane. There are common lessons about community engagement, risk perception and risk communication. Some guidelines will be proposed for ethical conduct of research with affected communities to better inform responses by authorities to future environmental disasters

CHAIRS

Michael Abramson

The Alfred Centre - Monash University | Department of Epidemiology and Preventive Medicine | Deputy Head | Australia

Erik Svendsen

Medical University of South Carolina (MUSC) | Public Health Sciences | Professor | United States of America



Michael Abramson

Shao Lin



Shunichi



Kazuhira Maehara



Fukuhara



Heidi J. Larson



Frik Svendsen

SPEAKERS

Michael Abramson

The Alfred Centre - Monash University | Department of Epidemiology and Preventive Medicine | Deputy Head | Australia

Long Term Health Effects Following a Fire in an Open Cut Coal Mine

Heidi J. Larson

London School of Hygiene & Tropical Medicine | Department of Infectious Disease Epidemiology | Director of the Vaccine Confidence Project | United Kingdom

Engaging Communities and Building Trust in Times of Uncertainty

Shao Lin

University at Albany | School of Public Health | Environmental Health Sciences | Professor | United States of America Long Term Follow-up of the World **Trade Center and Hurricane Sandy**

Erik Svendsen

Medical University of South Carolina (MUSC) | Public Health Sciences | Professor | United States of America **Community Recovery Following** a Mass Chlorine Leak

Shunichi Fukuhara

Kyoto University | School of Public Health | Dean Emeritus | Japan Sequelae of an Earthquake, Tsunami and Nuclear Crisis: 6 Years and a Half after March 11, 2011

DISCUSSANT

Kazuhira Maehara

Fukushima Medical University | Shirakawa Academy for General Medicine | Professor | Japan

WS 28

SAAL 5 | OCEANIA 11:00-12:30

MEDICAL RESEARCH IN OUTER SPACE



HOST

German Aerospace Center (DLR)

It is the overarching aim of this session to deal with the impact of environment, especially climate change, on human health and performance in space and on earth. Emphasis will be given on crosslinks between research topics such as ageing, cardiovascular, thermoregulatory, and psychological adaptations in space and other extreme environments.

Furthermore, advanced physiological monitoring and environmental simulation technologies designed for space and now used on earth will be presented. It will be seen that space technology and space medicine are today's drivers in innovation, helpful for the development of an effective personalized and preventive medicine in future health care.

PROGRAM, TUE 16

CHAIR

Jens Jordan

German Aerospace Center (DLR) | Institute of Aerospace Medicine | Director | Germany

SPEAKERS

Daniel Aeschbach

German Aerospace Center | Institute of Aerospace Medicine | Department of Sleep and Human Factors Research | Head | Germany

Hanns-Christian Gunga

Charité - Universitätsmedizin Berlin | Institute for Physiology | Director | Germany

Dietrich Manzey

Technical University of Berlin | Work, Engineering & Organizational Psychology | Head | Germany

Thomas Reiter

European Space Agency | ESA Interagency Coordinator | Germany



Daniel Aeschbach



Dietrich Manzey



Hanns-Christian Gunga



Thomas Reiter



Jens Jordan

KEYNOTE

KEY 04

SAAL 1 RUDOLF VIRCHOW 13:30-15:00

HEALTHY LIVES AND WELL-BEING FOR ALL

How Multi-Sectoral Cooperation makes a Difference



HOSTS

World Health Organization (WHO)

World Health Summit



The adoption of the 2030 Agenda for Sustainable Development has spurred opportunities for greater cohesion and maximizing effectiveness and efficiency across a spectrum of different sectors and stakeholders, including those involved in achievement of SDG3 and the health-related targets.

At present there is additional momentum towards greater synergy and cohesion as global health organizations engage in developing an SDG3 Action Plan, led by WHO. This partnership effort in moving the global health agenda forward also requires political engagement and financial support across all stakeholders who can contribute to health.

How can this be achieved? How should governments, civil society, the private sector and academia, in addition to multilateral health organizations, advance multilateral approaches and work together to strengthen global health governance so as to ensure healthy lives and well-being for all?

PROGRAM, TUE 16

CHAIR

Bernhard Schwartländer

World Health Organization (WHO) | Chef de Cabinet | Switzerland

SPEAKERS

Trevor Mundel

Bill & Melinda Gates Foundation | Global Health Division | President | United States of America

Caroline T. Roan

Pfizer Inc. | Corporate Responsibility | Vice President | United States of America Pfizer Foundation | President | United States of America

Peter Sands

The Global Fund to Fight AIDS, Tuberculosis and Malaria | Executive Director | Switzerland

H.E. Toyin Ojora Saraki

Wellbeing Foundation Africa | Founding President | Nigeria

Mariângela Simão

World Health Organization (WHO) | Assistant Director General, Access to Medicines, Vaccines and Pharmaceuticals | Switzerland



Trevor Mundel

H.E.Toyin Ojora Saraki



Caroline T. Roan

Bernhard Schwartländer



Peter Sands



Mariângela Simão

PANEL DISCUSSION

PD 10

SAAL 6 | EUROPE 13:30 - 15:00

THE DIGITAL HEALTHCARE REVOLUTION





HOSTS

Commonwealth Centre for Digital Health

Global Digital Health 2030 Innovation Task Force

A growing, ageing global population will have a profound impact on health spending across the world, predicted to rise to \$9.3 trillion by 2018. New technological developments are responding by increasingly blurring the boundaries between the physical, biological and digital worlds. Technology aims to personalize medicine in order to tailor treatments to individual patients based on their genetic makeup. This revolution has the potential to benefit the health of all and increase patient empowerment but it can also lead to new ethical challenges and increase health inequities.

In 2018, with the landmark passage of the World Health Assembly Resolution on "Digital Health" in May, and the call for the WHO Director General to deliver a "Global Strategy on Digital Health" to members states by May 2020, the stakes for advancing a truly global market in Universal Health Coverage (UHC) and the health-related Sustainable Development Goals (SDGs) by 2030 have taken on a new dimension. The next step is ensuring global cooperation and collaboration for the sustainability of innovations, their feasibility, scale-up and inclusivity.

CHAIR

Denis Gilhooly

Commonwealth Centre for Digital Health | Chief Strategy Officer | United Kingdom Global Digital Health 2030 Innovation Task Force | Founder & CEO

SPEAKERS

Christine Dingivan

Novartis | Portfolio Strategy and Innovation | Global Head | United States of America

Martin Hirsch

Assistance Publique - Hôpitaux de Paris (AP HP) | Director-General | France

Dykki Settle

PATH | Digital Health | Global Program Leader | United States of America

Päivi Sillanaukee

Ministry of Social Affairs and Health | Permanent Secretary | Finland

Despina Spanou

European Commission | Director for Digital Society, Trust and Cybersecurity | Belgium



Christine Dingivan

Dykki Settle



Denis Gilhooly

Päivi Sillanaukee



Martin Hirsch

Despina Spanou

KEYNOTE

KEY 05

SAAL 1 RUDOLF VIRCHOW 15:30-17:00

THE SDG3 GLOBAL ACTION PLAN FOR HEALTH AND WELL-BEING

Ensuring Impact where it Matters Most



HOSTS

World Health Organization (WHO)

World Health Summit



The ultimate success of the SDGs will be measured by their impact on the prosperity and well-being of people and the planet, particularly the extent to which the SDGs 'leave no one behind'. Initiatives such as the SDG3 Global Action Plan for health and well-being endeavour to build a foundation of greater cohesion among global health actors in support of countries' achievement of the healthrelated SDGs. But accelerating the pace of progress will require increased government cooperation at country level as well as enhanced stakeholder engagement across sectors - at global, regional, national and sub-national levels

This ministerial panel will discuss how best to catalyze political leadership to promote health, keep the world safe and serve the vulnerable as expressed in the shared purpose of WHO. It will explore the impediments and the keys to success for achieving these objectives, and propose how political actors can support a transformative approach to health and development.

CHAIR

Ilona Kickbusch

The Graduate Institute of International and Development Studies | Global Health Center | Director | Switzerland

SPEAKERS

Jens Spahn

Ministry of Health (BMG) | Minister of Health | Germany

Gerd Müller

Ministry for Economic Cooperation and Development (BMZ) | Minister for Economic Cooperation and Development | Germany

Jane Ruth Aceng

Ministry of Health | Minister of Health | Uganda

Verónica Espinosa

Ministry of Health | Minister | Ecuador

Tedros Adhanom Ghebreyesus

World Health Organization (WHO) | Director-General







Ilona Kickbusch



Verónica Espinosa

Gerd Müller



Tedros Adhanom Ghebreyesus

Jens Spahn

JKEY ESTREL HOTEL BERLIN 18:00-20:00

JOINT KEYNOTE

GRAND CHALLENGES / WORLD HEALTH SUMMIT

@ Estrel Hotel Berlin

HOSTS

Bill & Melinda Gates Foundation

German Federal Ministry of Education and Research (BMBF)

Grand Challenges

Grand Challenges Canada

United States Agency for International Development (USAID)

Wellcome Trust

World Health Summit















SPEAKERS INCLUDE

Angela Merkel

Federal Republic of Germany | Chancellor

Erna Solberg

Norway | Prime Minister

Tedros Adhanom Ghebreyesus

World Health Organization (WHO) | Director-General

Bill Gates

Bill & Melinda Gates Foundation | Co-Chair

Detley Ganten

World Health Summit | President



Angela Merkel

Bill Gates




Erna Solberg

Detlev Ganten



Tedros Adhanom Ghebreyesus



GENERAL INFORMATION

HOW TO GET TO THE WORLD HEALTH SUMMIT





From Tegel Airport (TXL)

Take the bus line "TXL" to "Alexanderplatz" and change to the underground line "U5" in the direction of "Hönow". Exit at the third stop at "Weberwiese". The Kosmos will be 300 meter down the road to the east.

Duration: about 60 minutes

Ticket: "Berlin Tarifgebiet A-B" (€ 2.80)

From Schönefeld Airport (SXF)

Take the train "RE7" in the direction of "Haupt-bahnhof", exit at "Alexanderplatz" and change to the underground line "U5" in the direction of "Hönow". Exit at the third stop at "Weberwiese". The Kosmos will be 300 meter down the road to the east

Duration: about 40 minutes

Ticket: "Berlin Tarifgebiet A-B-C" (€3.40)



From Berlin, Hauptbahnhof (Mainstation)

Take the train line "S7" in the direction of "Ahrensfelde", exit at "Alexanderplatz" and change to the underground line "U5" in the direction of "Hönow". Exit at the third stop at "Weberwiese". The Kosmos will be 300 meter down the road to the east.

Duration: about 20 minutes

Ticket: "Berlin Tarifgebiet A-B" (€2.80)

From Berlin, Alexanderplatz

Take the underground line "U5" in the direction of "Hönow". Exit at the third stop at "Weberwiese". The Kosmos will be 300 meter down the road to the east.

Duration: about 10 minutes

Ticket: "Berlin Tarifgebiet A-B" (€2.80)

By car

If you arrive by car you can use the underground parking lot right at the venue.

Berlin WelcomeCard

The Berlin WelcomeCard enables free travelling with all public transport services, discounts of at least 25% and up to 50% at around 200 participating partners, and a travel guide with various tour suggestions and insider tips. You can order your ticket at www.berlin-welcomecard.de/en

ACCESS TO THE VENUE / SECURITY

To enter the World Health Summit venue participants are required to present a valid identity card / passport or a similar personal identification document (photo included). Please be advised that due to security reasons, all participants will be subject to a security check including a passport identification confirmation. We kindly ask you to refrain from bringing your luggage to the venue, as this will slow down the security check process.

AVAILABILITY

Please note that the capacity of the venue and of single session rooms is limited. If the maximum number of participants is reached, the organizers reserve the right to refuse access.

CLOAKROOM

The cloakroom is located on the left side of the venue and open during the whole event.

COFFEE BREAKS

Refreshments will be served during the coffee breaks.

CURRENCY

The currency used in Berlin is the Euro (€ or EUR). Automated teller machines (ATMs), are located everywhere in Berlin and they accept most main credit cards such as Visa, Mastercard and American Express.

EMERGENCY NUMBERS

Fire: 112 Ambulance: 112 Police: 110

FILMING AND TAKING PICTURES

The organizer will provide a broad spectrum of pictures and other graphical material for the representation of all World Health Summit events. These files will be made available at www.worldhealthsummit.org.

HOMEPAGE

For up-to-date information regarding the World Health Summit, please visit www.worldhealthsummit.org.

INSURANCE AND LIABILITY

The organizers cannot accept liability for personal injury, loss of or damage to belongings of participants, either during or as a result of the World Health Summit. Please check the validity of your own insurance. Attendees are advised to arrange their own adequate travel and medical insurance for medical treatment, accidents, cancellation of bookings etc. No responsibility will be accepted by the World Health Summit organizers.

INTERNET/WIRELESS LAN

Complimentary Wi-Fi will be available within the venue:

Name: WorldHealthSummit Password: #WHS2018

LANGUAGE

The official World Health Summit language is English. There will be no simultaneous translation.

LUNCHES

Lunches will be available during the lunch breaks.

MEDIA

Media representatives have access to all official sessions of the World Health Summit. Prior accreditation is required via www.worldhealthsummit.org/media/accreditation

MOBILE PHONES

As a courtesy to speakers and other attendees, we kindly request that all mobile phones and similar devices will be turned to silent mode before entering a session.

NAME BADGE

A badge is required for admittance to all World Health Summit sessions and events. Each participant is asked to present the badge in order to gain access to the venue.

PEOPLE WITH DISABILITIES

The venue is accessible to participants with disabilities. Please contact the Secretariat for assistance: Phone: +49 30 49855031 or contact@worldhealthsummit.org

LOST AND FOUND

Lost items can be collected at the registration desk during the World Health Summit. Any objects found during the event and not claimed will remain at the venue.

LIVE-STREAM / WEBCASTS

All keynotes and panel discussions will be available as live-stream at www.worldhealthsummit.org

Recorded webcasts will be available online after the event.

PARKING

An underground parking lot right at the venue is available.

PROGRAM CHANGES

The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances. Please check the website for regular updates. The organizers reserve the right to cancel, postpone, relocate or change any of the sessions.

POSTERS

A poster exhibition will be located at the poster area in front of Saal 7 | Elizabeth Blackwell.

PUBLIC TRANSPORTATION

Berlin's public transport provides safe and comfortable rides to almost all destinations in the city. Tickets can be purchased directly at most train stations and in all busses.

More information: www.bvg.de

REGISTRATION

The registration desk is open during the following times:

Sunday, October 14, 2018	09:00 - 22:00
Monday, October 15, 2018	08:00 - 22:00
Tuesday, October 16, 2018	08:00 - 18:00

SMOKING POLICY

It is forbidden to smoke in any part of the World Health Summit venue.

147

SPEAKER CENTER

All speakers and presenters must report to the Speaker Center, located on the first floor, opposite of the entrance, at least two hours prior to their presentation in order to check and upload their presentation. Please provide the data on a USB memory stick or a CD-ROM. Please note that you cannot run the presentation from your personal laptop in the session room. Video support is at the sole responsibility of the speaker.

The Speaker Center is open during the following times:

Sunday, October 14, 2018	09:00 -18:00
Monday, October 15, 2018	08:00 -18:00
Tuesday, October 16, 2018	08:00 -17:00

TAXIS

All official taxis are colored off-white with a yellow taxi sign on the roof. The meter starts at a set minimum price.

Major Taxi Hotlines:

Taxi Berlin +49 30 202020 Taxi Würfelfunk +49 30 210101 Taxi Funk +49 30 443322

If there is no taxi available, please ask the registration desk staff for assistance.

TRAINING COURSE

Visiting physicians are accredited 6 points per day by the Berlin Chamber of Physicians. Please refer to the registration desk for further information.

BERLIN HEALTH EXCELLENCE EXPERTISE AND CUTTING-EDGE MEDICINE MADE IN BERLIN

Berlin's success as a health capital reflects a 300-year tradition as a healthcare and scientific centre. More than a dozen Nobel Prize winners worked here, including researchers such as Rudolf Virchow and Robert Koch. More than 90 hospitals with about 22,000 beds and with 9,900 doctors on duty, respectively an additional number of 9,200 doctors performing outpatient care make Berlin one of the cities with the highest numbers of doctors in Germany. Patients can thus find medical specialists for every disease. About 17,000 to 21,000 international patients are travelling to Berlin annually in order to undergo medical treatment.

One of Berlin's most famous medical institutions is the renowned Charité, Europe's largest university hospital and one of Germany's leading hospitals. Worldrenowned scientists of

For more information about Berlin as a meeting destination, go to convention.visitBerlin.com the Charité cooperate closely with recognized research organizations such as the Massachusetts Institute of Technology in Boston. Other famous examples are the German Heart Centre – a top-level hospital for heart and vascular diseases under the leadership of world famous heart surgeon Professor Dr. med. Volkmar Falk – or Vivantes – with its nine clinics and several rehabilitation centres being Germany's largest hospital group. Many more hospitals and doctor's surgeries could be mentioned as all of them are offering top-class medical treatment and provide medical experts of all disciplines.

Medical care at the highest level requires a strong collaboration between scientists and practitioners. Berlin is a leading centre of science and research in Europe, especially focusing on medicine. Four universities, the Charité teaching hospital, seven universities of applied sciences and over 30 private universities offer teaching and research facilities for people from all over the world. Germany's most important research organizations such as the Fraunhofer-Gesellschaft or the Max Planck Society are based in Berlin and successful technology parks like the tech-hub Adlershof or biotech park Campus Berlin-Buch established here.

This environment also makes Berlin a popular destination for international congresses in science and medicine: twenty per cent of the approximately 65,800 meetings, conventions and events held in the first half of 2018 were in the fields of medicine, healthcare and pharmaceuticals. International conferences such as the World Health Summit show that the German capital has been able to consolidate its strong position as a destination for medical events.

BERLIN - CAPITAL OF CULTURE

Apart from the excellent quality of medicine, the capital of Germany with its green character, several parks and leisure facilities offers many ways to relax or support the patients' recovery. Guests from abroad are increasingly investing in their health during their stay. It is only in Berlin that visitors can so perfectly combine health consciousness, culture and lifestyle.

Cultural experiences in Berlin are of great variety. From ancient art by the Old Masters to avant-garde design, from classical opera to musicals to pop concerts, Berlin's cultural calendar leaves nothing to be desired. For all seasons, at all hours and for every taste, Berlin has something to offer – 365 days a year, 24 hours a day. Visitors to the capital can choose from around 1,500 events a day.

Culture and art enthusiasts can also admire new styles and prominent works from all eras every day in Berlin's over 180 museums and approximately 440 galleries. The city's best known museums include the five buildings at Museum Island (Museumsinsel), which is in the historic centre. All buildings display valuable artistic treasures from 3,000 years of human history, e.g. the famous bust of Nefertiti in the New Museum, while the New National Gallery and Martin-Gropius-Bau present contemporary art.



Berlin is the world's only city to have three opera houses: the Berlin State Opera (Berliner Staatsoper), the Deutsche Oper and the Komische Oper. Classical music lovers can choose from a repertoire of famous works, such as Mozart's Don Giovanni, or new and experimental operas. Apart from these opera houses, the city's eight large orchestras, including the world famous Berlin Philharmonic conducted by Kirill Petrenko, also make for high-class musical enjoyment.

This autumn's cultural highlights include two top exhibitions in the Martin-Gropius-Bau: "Gurlitt: Status Report" shows around 250 artworks from the "2012 Munich artworks discovery", which caused a worldwide sensation. The exhibition not only makes works lost over decades accessible again, but also conveys the history behind each individual artwork. The exhibition "Restless Times. Archaeology in Germany", on the other hand, presents spectacular archaeological finds in Germany such as the Nebra Sky Disk.

"A Dedication of Love to Life": the new show "VIVID" at the Friedrichstadt Palast inspires with a spectacular stage design and unusual acrobatics. The extravagant headdress is the work of hat maker Philip Tracey, who has already worked for the Queen, Madonna and Lady Gaga.

Α	Boyle, Peter 51	E	Hachinski, Vladimir 69
Abramson, Michael 129	Braun, Ambassador	Eils, Roland 95	Hacker, Jörg 43
Aceng, Jane Ruth 137	Harald 47	Einhäupl, Karl Max 69	Hameed, Oladipupo 127
Adli, Mazda 55	Brötz-Oesterhelt, Heike 109	El-Noush, Haitham 115	Hamelin, Bernard 59
Aerts, Ann 117	Brun, Nikolai 59	ElWakil, Marwa 63	Hanvoravongchai, Piya 127
Aeschbach, Daniel 131	Buchsbaum, Steven 123	Engels, Dirk 81	Hassan, Mohamed H.A. 43,63
Agre, Peter 57	Buckley, Marc 97	Espinosa, Verónica 99,137	Heinze, Hans-Jochen 115
Akselrod, Svetlana 61	Bulmahn, Edelgard 63	Evans, Timothy Grant 101	Hildemann, Steven 113
Albiez, Peter 75	Burssa, Daniel 107		Hirsch, Martin 135
Alladi, Suvarna 69	Bwakura-Dangarembizi,	F	Hofer, Heribert 79
Alptekin, Ozan 57	Mutsa 47	Farrar, Jeremy 63,93	Hong, Felicia 65
Amin, Avni 103		Fears, Robin 43	Hörauf, Achim 109
Amuasi, John 87	С	Finnegan, John 117	Horváth, Ildikó 49
Arak, Barkin 57	Cardo, Denise 89	Frei, Ulrich 65	Hui, Kelvin 115
Artlich, Stefan 67	Castle, Evelyn 89	Fukuhara, Shunichi 45,129	Hyder, Adnan A. 113
Auler Jr., José Otávio Costa 57	Chawla, Mukesh 91		
Azevêdo, Maria Nazareth	Cheng, Shou-Hsia 45	G	I
Farani 105	Chin, Sylvie 97	Gabriel, Gülsah 79	Ibingira, Charles 121
	Coelho, Raquel 123	Ganapathi, Sindura 77	Ihekweazu, Chikwe 89
В	Cooper, Matthew 109	Ganten, Detlev 70,139	Ischinger, Wolfgang 75
Bahl, Rajiv 77	Cueni, Thomas B. 93	Gashumba, Diane 113	Iyasu, Solomon 119
Baptista Leite, Ricardo		Gates, Bill 139	lyer, Jayasree 93,125
Augustus Guerreiro 87	D	Geffert, Karin 121	
Barbi, Elisabetta 45	Davis, Steve 85	Gerst, Alexander 71	J
Barling, Mina 41	Degos, Laurent 49	Gewirtz-Meydan, Ateret 103	Jafarian, Ali 121
Bärnighausen, Till 85	de Graft Agyarko,	Ghazizadeh Hashemi,	Jager, Marjeta 101
Baur, Hans-Peter 107	Robert Kwame 101	Seyyed Hassan 75	Jakab, Zsuzsanna 41
Beier, Klaus Michael 103	Dessie, Yadeta 107	Ghebreyesus, Tedros	Jansen, Richard 87
Beissel von Gymnich,	Dhatt, Roopa 53	Adhanom 137,139	Jimenez, Carlos 99
Countess Jeannette 97	Dingivan, Christine 135	Gilhooly, Denis 135	Jocham, Uwe 57
Benn, Christoph 81	Dirnagl, Ulrich 95	Göhde, Roland 99	Jones, Monika 67
Berkley, Seth 75,85	Dora, Carlos 55	Göller, Christoph 97	Jordan, Jens 131
Bilgör, Timuçin 57	Doshi, Janavi 103	Grasselli, Nora Ilona 83	
Blackburn, Elizabeth 71	Doyen, Laurent 59	Grueger, Jens 87	K
Boehme, Catharina 47	Dräger, Stefan 77	Gunga, Hanns-Christian 131	Kabatereine, Narcis 81
Boisjoly, Hélène 41	Draghia, Ruxandra 91		Kabia, Evelyn 53
Boufford, Jo Ivey 83,117	Drosten, Christian 75	Н	Karam, Azza 63

Haas, Oliver 107

Kariuki, Thomas 123

Durkin, Mike 65

Bourla, Albert 71

Sy, Elhadj As 41

Käsermann, Fabian 57	Martinez, Georgina Garcia 99	P	Schmitt-Lord, Thimo V. 96
Katz, Gregory 87	McGrath, Peter 83	Panzani, Sonia 89	Schneider, Gisela 67,107
Kaufmann, Stefan H.E. 47	McGuire, Helen 123,125	Pavlin, Boris 89	Schrade, Christina 53
Kauki, George C. 89	Mciff, Colin 105	Peeters, Jaak 75	Schütte, Georg 93
Kavak, Erşen 57	McNamara, Tracey 91	Peire, Eduardo 97	Schwartländer, Bernhard 133
Khachaturian, Zaven 69	Merkel, Angela 139	Pelletier, François 55	Seith, Alexander 97
Kickbusch, Ilona 105,127,137	Merson, Michael H. 121	Penk, Andreas 51	Sendegeya, Augustin 107
Kiefer, Annegret 107	Mikkelsen, Bente 61	Perrin, Nicola 95,119	Senn, Stephen 95
Kippels, Georg 99	Miyashita, Jun 45	Perry, Greg 125	Settle, Dykki 135
Kluge, Ulrike 55	Modig, Karin 45	Peters, Annette 119	Sewankambo, Nelson 117
Köhler, Carsten 81	Moeti, Matshidiso	Piddock, Laura 109	Shaligram, Umesh 47
Krause, Gérard 47,89	Rebecca 71	Piot, Peter 101	Shu, Yuelong 79
Kray, Ralph 56	Moll, Nathalie 87	Pischon, Tobias 119	Sidibé, Michel 99
Krech, Rüdiger 113	Montag, Bernd 95	Prainsack, Barbara 95	Sillanaukee, Päivi 105,135
Kristensen, Frederik	Morgan, Rosemary 53	Pries, Axel Radlach 49,121	Silva, João Gabriel 70
Kristen Ole 85	Möröy, Tarik 49		Silver, Karlee 41,123
Krüger, Susanna 41	Moser, Heinz 109	R	Silverstein, Alex 59
Kümmel, Björn 105	Mujumdar, Sandhya 65	Rastegar, Asghar 121	Simão, Mariângela 125,133
	Müller, Gerd 71,137	Rath, Barbara 79	Sipido, Karin R. 49
L	Müller, Rolf 93,109	Rau, Roland 45	Sjöden, Anna Lönnroth 49
Larijani, Bagher 61	Mumford, Elizabeth 91	Razum, Oliver 121	Slingsby, BT 75
Larson, Heidi J. 129	Mundel, Trevor 133	Regateiro, Fernando J. 57,70	Smith, Gayle E. 85
Lee, Diana 67	Murphy, Diarmuid 87	Reiter, Thomas 131	Solaroglu, Ihsan 57
Lichtner, Katharina 77	Mutapi, Francisca 81	Riboli, Elio 119	Solberg, Erna 139
Likaka, Andrew 115,127		Richards-Kortum,	Spahn, Jens 71,137
Lin, Shao 129	N	Rebecca 77	Spanou, Despina 135
Lippert, Christoph 119	Neci, Richard 67	Roan, Caroline T. 133	Sprenger, Marc 79
Liu, Depei 57	Nicotera, Pierluigi 69	Röttger, Maike 105	Stanton, David 115
Luescher, Bettina 97	Nietlisbach, André 56	Rowe, Brian H. 69	Staudinger, Roland 65
	Nieuwenhuijsen, Mark 117		Steutel, Han 67
M	Nimmesgern, Elmar 91	S	Stoffels, Paul 101
Mabizela, Rev'd Phumzile 63	Nordström, Anders 61	Salama, Peter 101	Stowasser, Bernd 49
Madeja, Michael 107		Samavati, Sahar 55	Stuart, Lynda Maria 85
Maehara, Kazuhira 129	0	Sands, Peter 133	Sullivan, Richard 51
Mahomed, Faraaz 55	Okolo, Stanley 101	Santerre, Frédérique 125	Sun, Xiaochun 63
Makanga, Michael 47	Omete, Edward 61	Saraki, H.E. Toyin Ojora 133	Svendsen, Erik 129
Manzey, Dietrich 131	Oschmann, Stefan 71	Saxena, Subhanu 125	Syed, Shamsuzzoha Babar 10
M. Iller Birler IB F7	O	6 6 107	C Ell. 1: A . 41

Schlacke, Sabine 127

Owen, Katey Einterz 81

Markham, Richard B. 57

SUPPORTING INSTITUTIONS

Т	A		
Takian, Amirhossein 127	Association of Research-based Pharmaceutical Companies (vfa) 66,80		
Teo, Yik-Ying 119			
ter Kuile, Feiko 47	В		
ter Meulen, Volker 43	Bayer Foundations 96		
Thompson, Kelly 53	Berlin Institute of Health (BIH) 94		
Tilg, Bernhard 59	Bill & Melinda Gates Foundation 76,84,122,138		
Tkalec, Suzanna 99			
Torode, Julie S. 51	C		
	Charité - Universitätsmedizin Berlin 54,58,64,68,94,102,118,120		
U	Cluster Médico Jalisco AC 98		
Ulfendahl, Mats 49	Commonwealth Centre for Digital Health 134		
V	E		
Varma, Jay 89	Eberhard-Karls-University Tübingen 80		
Venkateswaran, Sandhya 113	ESMT European School of Management and Technology GmbH 82		
Vera, Facundo Gomez 97	European and Developing Countries Clinical Trials Partnership (EDCTP) 46		
Verschure, Paul 63	European Commission 48		
Vogler, Sabine 51			
von Braun, Joachim 43	F		
von Dobschuetz, Sophie 91	Federal Ministry for Economic Cooperation and Development (BMZ)		
von Weiler, Julia 103	100,106,114,126		
	Fliedner Klinik Berlin 54		
W	Foundation for Innovative New Diagnostics (FIND) 46		
Watts, Charlotte 75			
Wieler, Lothar H. 93	G		
Willich, Stefan 59	German Aerospace Center (DLR) 130		
Wilson, David Randolph 89	German Center for Infection Research e.V. (DZIF) 92,108		
Wilson, James 91	German Federal Ministry of Education and Research (BMBF) 78,92,108,138		
Wood, Tim 115	German Federal Ministry of Health (BMG) 104		
	German Healthcare Partnership (GHP) 98		
Υ	German Institute for Defence and Strategic Studies (GIDS) 90		
Yang, Dazhu 51	German National Academy of Sciences Leopoldina e.V. 42		
Yonga, Gerald 61,125	German Network against Neglected Tropical Diseases (DNTDs) 80		
Yon, Lisa 91	German Society for International Cooperation (GIZ) 114		
	German Society for Tropical Medicine and International Health (DTG) 80		
Z	Global Digital Health 2030 Innovation Task Force 134		
Zacharuk Alexander 97	Global Health Security Alliance 90		

Grand Challenges 76.122.138 Grand Challenges Canada 138 National Taiwan University (NTU) 44 National University of Singapore (NUS) 64,86 Heidelberg Institute of Global Health 84 Helmholtz Centre for Infection Research (HZI) 88.108 PATH 84 Pfizer 50 Т Imperial College London 64 R InterAcademy Partnership (IAP) 42,62,82,116 Research in Gender Ethics (RinGs) 52 International Federation of Pharmaceutical Manufacturers & Robert Koch Institute 92 Associations (IFPMA) 124 International Partnership on Religion and Sustainable Sanofi 58.60 Development (PaRD) 62 International Prevention Research Institute (iPRI) 50 International Society for Urban Health (ISUH) 116 Tehran University of Medical Sciences (TUMS) 120 The Else Kröner-Fresenius Stiftung 106 Johns Hopkins Bloomberg School of Public Health 112 The NCD Alliance 60 Joint United Nations Programme on HIV/AIDS (UNAIDS) 98 Κ United States Agency for International Development KfW Group 100 (USAID) 138 Kyoto University 44 Universitätsklinikum Tübingen 80 University of Montreal 40 University of Rostock 44 Leibniz Association 78 London School of Hygiene & Tropical Medicine (LSHTM) 128 W Wellcome Trust 138 М Women in Global Health 52 M8 Alliance 56.68.70.120 World Dementia Council (WDC) 68 Makerere University 120 World Federation of Academic Institutions for Global Max-Delbrück-Centrum für Molekulare Medizin (MDC) 118 Health (WFAIGH) 116 Max Planck Society 44,46 World Health Organization (WHO) 60,132,136 Ministry of Economic Affairs Canton of Bern 56 World Health Summit 132,136,138 Monash University 128 World Stroke Organization (WSO) 68 Munich Security Conference (MSC) 74

SPONSORING PARTNERS

Strategic Partners










Major Partners













Federal Ministry

of Education

and Research







Gerneral Partners



























SUPPORTING PARTNERS









































SERVICE PARTNERS









POLICY MAKERS







ACADEMIA



























































CIVIL SOCIETY

















































ASSOCIATES





































MEDIA PARTNERS





















Media Registrations

Media Registrations are available free of charge to journalists (pending proof of affiliation).

Prior to the World Health Summit, please apply for your registration online via

www.worldhealthsummit.org/media/accreditation

During the event, please contact the media accreditation counter at the registration desk.

PRESS CONTACT Antje Schütt & Daniela Levy communications@worldhealthsummit.org Phone: +49 30 450 572 114

PRESS CONFERENCE SUNDAY, OCTOBER 14, 11:30-12:30 Outdoor | Robert Koch

Media Access

Media has access to all official sessions of the World Health Summit.

Media Center

First floor, opposite of the venue entrance

The media center can be used during the whole World Health Summit







WHS Foundation GmbH

c/o Charité -Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin, Germany

World Health Summit Presidents

João Gabriel Silva Fernando Regateiro Detlev Ganten

Managing Director

Jörg Heldmann joerg.heldmann@charite.de Tel.: +49 30 450 572 118

Fax: +49 30 450 517 911

Program Director

Julian Kickbusch julian.kickbusch@charite.de Tel.: +49 30 450 572 122

Fax: +49 30 450 517 911

Press & Public Relations Director

Antje Schütt antje.schuett@charite.de

Tel.: +49 30 450 572 114 Fax: +49 30 450 517 911

Strategic Communications Director

Daniela Levy

daniela.levy@charite.de Tel.: +49 30 450 572 114

Fax: +49 30 450 517 911

PA to the Founding President

Pascale Schulte

pascale.schulte@charite.de

Tel.: +49 30 450 572 102 Fax: +49 30 450 517 911

Director of Operations

Petra Neitzel

petra.neitzel@charite.de

Tel: +49 30 450 572 219 Fax: +49 30 450 517 911

Organizing Secretariat

Agentur WOK GmbH Palisadenstraße 48 10243 Berlin, Germany

Registration Department

Stefanie Kuch-Steudemann, Lena Strauß

www.worldhealthsummit.org

Photo Credits

Angela Merkel, Page 8, 139 © Bundesregierung / S. Kugler Charité - Universitätsklinik, Page 14 © Charité Kosmos, Page 19 © Kosmos KG Bärbel-Maria Kurth, Page 21 © Robert Koch-Institut / Dugnus Eckart von Hirschhausen, Page 22 © Frank Eidel Fernsehturm Alexanderplatz, Page 35 Photo: golero © iStockphoto Peter Agre, Page 57 © Will Kirk, Johns Hopkins University Ulrich Frei, Page 65 © Uwe Nölke World Doctors Orchestra, Page 70 © Meike Böschemeyer, Bonn 2013 Ulrich Dirnagl, Page 95 © BIH - Thomas Rafalzyk Michel Sidibé, Page 99 © UNAIDS Julia von Weiler, Page 103 © ZDF Tobias Pischon, Page 119 Photo: David Ausserhofer © MDC Thomas Reiter, Page 131 © J. Mai Charité - Universitätsklinik, Page 148 © Charité Gendarmenmarkt, Page 149 © Gutscherra/Osthoff

Layout

Eta Friedrich, Berlin

Printer

Laserline, Berlin

World Health Summit

WHS Foundation GmbH c/o Charité - Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin Germany

Tel.: +49 30 450 572102 Fax: +49 30 450 572911

secretariat@worldhealthsummit.org www.worldhealthsummit.org

SAVE THE DATES



WORLD HEALTH SUMMIT REGIONAL MEETING

KISH ISLAND, IRAN APRIL 29-30, 2019

WORLD HEALTH SUMMIT

BERLIN, GERMANY OCTOBER 27-29, 2019



www.worldhealthsummit.org